

GenCore version 5.1.4_p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 9, 2003, 18:38:27 ; Search time 6228 Seconds
(without alignments)
11467.291 Million cell updates/sec

Title: US-09-973-827-3
Perfect score: 2454
Sequence: 1 cggcggggaggtgtgtttg.....tcgtattgtgtatcatc 2454

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0
Searched: 2054640 seqs, 14551402878 residues 841850

Total number of hits satisfying chosen parameters: 841850
Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

- GenEmbl:*
- 1: gb_ba:*
 - 2: gb_btg:*
 - 3: gb_in:*
 - 4: gb_em:*
 - 5: gb_ov:*
 - 6: gb_pat:*
 - 7: gb_ph:*
 - 8: gb_pi:*
 - 9: gb_pr:*
 - 10: gb_ro:*
 - 11: gb_sts:*
 - 12: gb_sy:*
 - 13: gb_un:*
 - 14: gb_vi:*
 - 15: em_ba:*
 - 16: em_fun:*
 - 17: em_hum:*
 - 18: em_in:*
 - 19: em_mu:*
 - 20: em_om:*
 - 21: em_or:*
 - 22: em_pat:*
 - 23: em_ph:*
 - 24: em_pi:*
 - 25: em_ro:*
 - 26: em_sts:*
 - 27: em_un:*
 - 28: em_vi:*
 - 29: em_vt:*
 - 30: em_htg_hum:*
 - 31: em_htg_inv:*
 - 32: em_htg_other:*
 - 33: em_htg_mus:*
 - 34: em_htg_pln:*
 - 35: em_htg_rod:*
 - 36: em_htg_mam:*
 - 37: em_htg_vrt:*
 - 38: em_sy:*
 - 39: em_htgo_hum:*
 - 40: em_htgo_mus:*
 - 41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	27	1.1	27	6 AR090566	AR090566 Sequence
C 2	27	1.1	27	6 AR197601	AR197601 Sequence
C 3	26	1.1	26	6 AR090565	AR090565 Sequence
C 4	26	1.1	26	6 AR197600	AR197600 Sequence
C 5	25	1.0	49	1 ECOINSM	M11752 E.coli inse
C 6	23.2	0.9	50	10 NMU41943	U41943 Mus musculus
C 7	23	0.9	50	6 AX161232	AX161232 Sequence
C 8	22.4	0.9	50	6 AX157048	AX157048 Sequence
C 9	22.2	0.9	43	6 AX483407	AX483407 Sequence
C 10	22	0.9	47	6 AX319484	AX319484 Sequence
C 11	22	0.9	48	6 AX319485	AX319485 Sequence
C 12	21.4	0.9	41	6 AX045523	AX045523 Sequence
C 13	21.2	0.9	45	6 A19511	A19511 oligonucleo
C 14	21.2	0.9	48	6 AX223683	AX223683 Sequence
C 15	21	0.9	43	6 AX484546	AX484546 Sequence
C 16	21	0.9	50	6 AR022597	AR022597 Sequence
C 17	21	0.9	50	6 AR037612	AR037612 Sequence
C 18	21	0.9	50	6 AR178070	AR178070 Sequence
C 19	21	0.9	50	6 AX160550	AX160550 Sequence
C 20	20.8	0.8	43	6 AX166164	AX166164 Sequence
C 21	20.8	0.8	43	6 E33229	E33229 Novel metha
C 22	20.8	0.8	45	6 AX320846	AX320846 Sequence
C 23	20.8	0.8	45	6 AX320847	AX320847 Sequence
C 24	20.8	0.8	48	6 AX428511	AX428511 Sequence
C 25	20.8	0.8	48	9 HS295110	295110 H.sapiens m
C 26	20.8	0.8	49	6 AX456410	AX456410 Sequence
C 27	20.6	0.8	36	6 E14547	E14547 DNA probe f
C 28	20.6	0.8	40	6 AR149458	AR149458 Sequence
C 29	20.6	0.8	40	6 E49430	E49430 Method for
C 30	20.6	0.8	43	6 AX484404	AX484404 Sequence
C 31	20.6	0.8	44	6 AR172650	AR172650 Sequence
C 32	20.6	0.8	45	9 HUMADSB1	M60135 Human/HIV 5
C 33	20.6	0.8	48	6 AX223789	AX223789 Sequence
C 34	20.6	0.8	48	6 AX426775	AX426775 Sequence
C 35	20.6	0.8	50	6 AR120175	AR120175 Sequence
C 36	20.6	0.8	50	6 AR126173	AR126173 Sequence
C 37	20.6	0.8	50	6 AR177989	AR177989 Sequence
C 38	20.6	0.8	50	6 AX061557	AX061557 Sequence
C 39	20.4	0.8	40	6 AR013538	AR013538 Sequence
C 40	20.4	0.8	40	6 AR109499	AR109499 Sequence
C 41	20.4	0.8	40	6 I55670	I55670 Sequence
C 42	20.4	0.8	40	6 I76447	I76447 Sequence
C 43	20.4	0.8	48	6 AR032406	AR032406 Sequence
C 44	20.4	0.8	48	6 AR209070	AR209070 Sequence
C 45	20.4	0.8	48	6 AX223778	AX223778 Sequence

ALIGNMENTS

RESULT 1
AR090566/c
LOCUS AR090566
DEFINITION Sequence 686 from patent US 5994076.
ACCESSION AR090566
VERSION AR090566.1 GI:10017321
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 27)
Chenchik, A., Tokhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 686 30-NOV-1999;
FEATURES Location/Qualifiers

27 bp DNA linear PAT 07-SEP-2000

```

source 1. .27
BASE COUNT 4 a 4 c 10 g 9 t
ORIGIN

Query Match 1.1% Score 27; DB 6; Length 27;
Best Local Similarity 100.0%; Pred. No. 4.9e+05;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 827 ATACGAGATTCGCACACCCACTAG 853
Db 27 ATACGAGATTCGCACACCCACTAG 1

RESULT 2
ARI97601/c
LOCUS ARI97601 27 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 686 from patent US 6352829.
ACCESSION ARI97601
VERSION ARI97601.1 GI:20247450
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 27)
  Chenchik, A., Jokhadze, G. and Bibilashvili, R.
  Methods of assaying differential expression
  Patent: US 6352829-A 686 05-MAR-2002;
  JOURNAL Location/Qualifiers
  FEATURES
    source 1. .27
    /organism="unknown"
BASE COUNT 4 a 4 c 10 g 9 t
ORIGIN

Query Match 1.1% Score 27; DB 6; Length 27;
Best Local Similarity 100.0%; Pred. No. 4.9e+05;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 827 ATACGAGATTCGCACACCCACTAG 853
Db 27 ATACGAGATTCGCACACCCACTAG 1

RESULT 3
ARI90565
LOCUS ARI90565 26 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 685 from patent US 5994076.
ACCESSION ARI90565
VERSION ARI90565.1 GI:10017320
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 26)
  Chenchik, A., Jokhadze, G. and Bibilashvili, R.
  Methods of assaying differential expression
  Patent: US 5994076-A 685 30-NOV-1999;
  JOURNAL Location/Qualifiers
  FEATURES
    source 1. .26
    /organism="unknown"
BASE COUNT 9 a 5 c 9 g 3 t
ORIGIN

Query Match 1.1% Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 7.7e+05;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 507 GCACCAGAGTGCCACAGGATTGAAGA 532
Db 1 GCACCAGAGTGCCACAGGATTGAAGA 26

RESULT 4
ARI97600
LOCUS ARI97600 26 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 685 from patent US 6352829.
ACCESSION ARI97600
VERSION ARI97600.1 GI:20247449
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 26)
  Chenchik, A., Jokhadze, G. and Bibilashvili, R.
  Methods of assaying differential expression
  Patent: US 6352829-A 685 05-MAR-2002;
  JOURNAL Location/Qualifiers
  FEATURES
    source 1. .26
    /organism="unknown"
BASE COUNT 9 a 5 c 9 g 3 t
ORIGIN

Query Match 1.1% Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 7.7e+05;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 507 GCACCAGAGTGCCACAGGATTGAAGA 532
Db 1 GCACCAGAGTGCCACAGGATTGAAGA 26

RESULT 5
ECOINSW
LOCUS ECOINSW 49 bp DNA linear BCT 26-APR-1993
DEFINITION E.coli insertion site for transposon Tn1545.
ACCESSION M31752
VERSION M31752.1 GI:146490
KEYWORDS
SOURCE E.coli DNA.
ORGANISM Escherichia coli
REFERENCE
  1 (bases 1 to 49)
  Caillaud, F. and Courvalin, P.
  Nucleotide sequence of the ends of the conjugative shuttle
  transposon Tn1545
  Mol. Gen. Genet. 209 (1), 110-115 (1987)
  JOURNAL
  MEDLINE 88038347
  PUBMED 2823065
  FEATURES
    Location/Qualifiers
    source 1. .49
    /organism="Escherichia coli"
    /db_xref="taxon:562"
BASE COUNT 12 a 10 c 0 g 27 t
ORIGIN

Query Match 1.0% Score 25; DB 1; Length 49;
Best Local Similarity 75.6%; P-ed. No. 1.1e+06;
Matches 31; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

OY 2300 CAATATTGGATTGTCATTCTTACAAACATTTTTCCTC 2340
Db 8 CAATTTCTCTTTTATTATTATTAATAATCATTTTTCCTC 48

RESULT 6
MMU41943/c
LOCUS MMU41943 50 bp DNA linear ROD 05-JAN-1996
DEFINITION Mus musculus recombination between immunoglobulin heavy chain and
  c-myc.
ACCESSION U41943
VERSION U41943.1 GI:1147577
KEYWORDS
SOURCE house mouse strain-BALB/can.
ORGANISM Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

REFERENCE Mammalia: Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 AUTHORS 1 (bases 1 to 50)
 TITLE Muller, J.R.
 JOURNAL Direct Submission
 FEATURES Submitted (05-DEC-1995) Jurgan R. Muller, Lab of Genetics, NIH/NCI,
 8109. 37, Room 2B09, 37 Convent Dr., Bethesda, MD 20892-4255, USA
 Location/Qualifiers
 1..50
 /organism="Mus musculus"
 /strain="BALB/cAn"
 /db_xref="taxon:10090"
 /chromosome="T(12:15)"
 /map="T(12f1:15d2)"
 /tissue_type="Peyer's patch 7 days post pristane"
 /dev_stage="7 days post pristane"
 12 a 11 c 18 g 9 t

BASE COUNT 12 a 11 c 18 g 9 t
 ORIGIN
 Query Match 0.9%; Score 23.2; DB 10; Length 50;
 Best Local Similarity 77.8%; Pred. No. 2.6e+06;
 Matches 28; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1473 CAGATTACCCAGCCTCTTGAGCTGAAGTAATGCTG 1508
 Db 37 CAGATACCCAGCCTTTTGAGCTGAGCTAGGCTG 2

RESULT 7
 AX161232/c
 LOCUS AX161232
 DEFINITION Sequence 4560 from Patent WO0140521.
 ACCESSION AX161232
 VERSION AX161232.1 GI:14542563
 KEYWORDS human.
 SOURCE Homo sapiens
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 50)
 Shinkels, R.A. and Leach, M.
 Nucleic acids containing single nucleotide polymorphisms and
 methods of use thereof
 Patent: WO 0140521-A 4560 07-JUN-2001;
 Curagen Corporation (US)
 Location/Qualifiers
 1..50
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 25..26
 /note="Nucleotide deleted between bases 25 and 26"
 Accession number Cg43958770"

BASE COUNT 16 a 4 c 5 g 25 t
 ORIGIN
 Query Match 0.9%; Score 23; DB 6; Length 50;
 Best Local Similarity 74.4%; Pred. No. 2.8e+06;
 Matches 29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1160 AAAGACAAATAACATTTATTTCTAAACATTTCTT 1198
 Db 39 AATGGAAAAAACCCTTGTTATTTGTAAATATTTCTT 1

RESULT 8
 AX157048
 LOCUS AX157048
 DEFINITION Sequence 376 from Patent WO0140521.
 ACCESSION AX157048
 VERSION AX157048.1 GI:14538379
 KEYWORDS human.
 SOURCE human.

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 (bases 1 to 50)

AUTHORS

Shinkels, R.A. and Leach, M.

TITLE

Nucleic acids containing single nucleotide polymorphisms and

JOURNAL

Patent: WO 0140521-A 376 07-JUN-2001;

FEATURES

Curagen Corporation (US)

SOURCE

Location/Qualifiers

1..50

/organism="Homo sapiens"

/db_xref="taxon:9606"

25..26

/note="Nucleotide deleted between bases 25 and 26"

Accession number Cg44921986"

BASE COUNT 15 a 3 c 6 g 26 t

ORIGIN

Query Match 0.9%; Score 22.4; DB 6; Length 50;

Best Local Similarity 66.7%; Pred. No. 3.7e+06;

Matches 32; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2310 ATTTCATCTTACAAACATTTTCTCTCTGTGAAAAAGAGTAG 2357

Db 1 ATTTTCTTAAAAAATTTTGTGTTTAACTACAGAGGAG 48

RESULT 9

AX483407/c

LOCUS AX483407

DEFINITION Sequence 707 from Patent WO02053728.

ACCESSION AX483407

VERSION AX483407.1 GI:22317827

KEYWORDS

Candida albicans.

Candida albicans

Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;

Saccharomycetales; mitosporic Saccharomycetales; Candida.

1

Roemer, T., Jiang, B., Boone, C., Bussey, H. and Ohlsen, K.L.

Gene disruption methodologies for drug target discovery

Patent: WO 02053728-A 707 11-JUL-2002;

Elitra Pharmaceuticals, Inc. (US)

Location/Qualifiers

1..43

/organism="Candida albicans"

/db_xref="taxon:5476"

6 a 13 c 1 g 23 t

BASE COUNT

ORIGIN

Query Match 0.9%; Score 22.2; DB 6; Length 43;

Best Local Similarity 69.8%; Pred. No. 4.1e+06;

Matches 30; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 152 TGGAGATGCGCTGTAACAGAGCTGAAACCAACCAATGCA 194

Db 43 TGGAGTTGAATCTGGAAAAGAGGAAGGAGGAAATGAAA 1

RESULT 10

AX319484/c

LOCUS AX319484

DEFINITION Sequence 13 from Patent WO0182962.

ACCESSION AX319484

VERSION AX319484.1 GI:17901270

KEYWORDS

Human immunodeficiency virus.

Human immunodeficiency virus

Viruses; Retrovirdae; Retrovirdae; Lentivirus; Primate

Lentivirus group.

1

```

/db_xref="taxon:32630"
/note="Synthetic"
19 a      4 c      5 g      13 t

Query Match          0.9%; Score 21.4; DB 6; Length 41;
Best Local Similarity 71.8%; Pred. No. 5.9e+06;
Matches 28; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1855 ATTTAAATTAAGCAAGAATAAATAAAGTACGAAGCAT 1893
|||||  |||||  |||||  |||||  |||||  |||||  |||||
1 ATGTTAGATACAATAAAGTATATGAATTTCAAATCAT 39

RESULT 13
LOCUS       A19511                      45 bp    DNA                linear        PAT 10-JUN-1994
DEFINITION  Oligonucleotide 61-83 Hepatitis A virus.
ACCESSION   A19511
VERSION     A19511.1 GI:583227
KEYWORDS    .
SOURCE      synthetic construct.
            synthetic construct
            artificial sequences.
            1 (bases 1 to 45)
REFERENCE   Brown,A.L., Clarke,B.E. and Rowlands,D.J.
AUTHORS    Chimeric hepatitisvirus core antigen proteins
TITLE       Patent: Ep 0421635-A 37 10-APR-1991;
JOURNAL     THE WELLCOME FOUNDATION LIMITED
FEATURES    Location/Qualifiers
             ..45
             /organism="synthetic construct"
             /db_xref="taxon:32630" 10 t

BASE COUNT      11 a      11 c      13 g      10 t

Query Match          0.9%; Score 21.2; DB 6; Length 45;
Best Local Similarity 69.0%; Pred. No. 6.3e+06;
Matches 29; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 604 CTAGCAGTGGACAGTATATTGCCATTACCAGCGAGGAGCAA 645
|||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 2 CTAGCACTGAACAGAAATCTCCGCATCTCAGGTGGAGCTA 43

RESULT 14
LOCUS       AX223683                     48 bp    mRNA                linear        PAT 07-SEP-2001
DEFINITION  Sequence 9125 from Patent WO0159103.
ACCESSION   AX223683
VERSION     AX223683.1 GI:15551407
KEYWORDS    .
SOURCE      synthetic construct.
            synthetic construct
            artificial sequences.
            1 (bases 1 to 48)
REFERENCE   Blatt,L., McSwiggen,J. and Chowrira,B.M.
AUTHORS     Method and reagent for the modulation and diagnosis of cd20 and
TITLE       nogo gene expression
JOURNAL     Patent: WO 0159103-A 9125 16-AUG-2001;
            RIBOZYNE PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
            McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES    Location/Qualifiers
             ..48
             /organism="synthetic construct"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
             12 a      12 c      16 g      8 t

BASE COUNT      12 a      12 c      16 g      8 t

Query Match          0.9%; Score 21.2; DB 6; Length 48;
Best Local Similarity 69.0%; Pred. No. 6.3e+06;
Matches 29; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

```


OM nucleic - nucleic search, using sw model

Run on: March 9, 2003, 18:19:02 : Search time 510 Seconds
(without alignments)
10836.086 Million cell updates/sec

Title: US-09-973-827-3
Perfect score: 2454
Sequence: 1 cgcggcgggggtgtgtgtg.....tctgtatttggatatcat 2454

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2166140

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_10:002:.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT:.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT:.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT:.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT:.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT:.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT:.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT:.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT:.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT:.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT:.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT:.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT:.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT:.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT:.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT:.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT:.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT:.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT:.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT:.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT:.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT:.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT:.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT:.*
24: /SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query No.	Score	Match	Length	DB ID	Description
C 1	27	1.1	27	24	ABK65598	Human gene specific
C 2	26	6	47	21	ABK67081	Human map-related
C 3	26	1.1	26	24	ABK65597	Human gene specific
C 4	24	1.0	34	24	ABK40868	CREB cDNA amplifi
C 5	24	1.0	34	24	ABK40870	CREB cDNA amplifi
C 6	23	4	31	19	AAV211495	Plasmid PRSV-CREB3
C 7	23	4	1.0	47	AAV211495	Human map-related
C 8	23	0.9	50	22	AAV17619	Human silent SNP c
C 9	22	6	50	22	AAL34381	Human SNP oligonuc

c 11	22.4	0.9	50	22	AAV173435	Human silent SNP c
c 12	22.2	0.9	45	17	AAV07082	Primer EXD0.1, amp
c 13	22	0.9	33	24	ABL40867	CREB cDNA amplifi
c 14	22	0.9	46	24	ABL01753	Human MSH2 (HMSR2)
c 15	22	0.9	47	24	AAV171996	VCPI579 primer HIV
c 16	22	0.9	48	24	AAV171997	VCPI579 primer HIV
c 17	21.6	0.9	47	21	AAV267881	Human map-related
c 18	21.6	0.9	49	20	AAV350326	Trailer oligonucle
c 19	21.4	0.9	40	13	AAQ25032	Oligonucleotide sp
c 20	21.4	0.9	41	21	AAV87847	Bacillus thuringie
c 21	21.4	0.9	50	22	AAL28587	Human SNP oligonuc
c 22	21.4	0.9	50	22	AAL28587	Human SNP oligonuc
c 23	21.2	0.9	30	20	AAV16677	CREB341 phosphoryl
c 24	21.2	0.9	45	12	AAQ11255	Encodes Hepatitis
c 25	21.2	0.9	48	23	AAK09125	Human CD40 Ambery
c 26	21.2	0.9	50	22	AAK09125	Plasmid PRSV-CREB3
c 27	21	0.9	32	19	AAV21501	CREB341 phosphoryl
c 28	21	0.9	33	20	AAV76678	Human map-related
c 29	21	0.9	47	21	AAV269260	Human silent SNP c
c 30	20.8	0.8	50	22	AAV175937	Primer Bayqk-Gl fo
c 31	20.8	0.8	43	21	AAV261260	HaEPV transfer vec
c 32	20.8	0.8	45	21	AAV255674	Human map-related
c 33	20.8	0.8	47	21	AAV269043	Human map-related
c 34	20.8	0.8	48	24	A3K22203	Human ERG ambery
c 35	20.8	0.8	49	24	A3L99285	Synthetic Renilla
c 36	20.8	0.8	50	22	AAL34100	Human SNP oligonuc
c 37	20.6	0.8	50	22	AAL34577	Human SNP oligonuc
c 38	20.6	0.8	36	19	AAV35962	Nucleotide sequenc
c 39	20.6	0.8	40	22	AAK36843	Human c-fos strept
c 40	20.6	0.8	44	21	AAV290218	Wild-type phoA pro
c 41	20.6	0.8	44	24	ABL36027	A. thaliana connec
c 42	20.6	0.8	44	24	ABL36030	A. thaliana connec
c 43	20.6	0.8	48	23	ABK09231	Human CD20 Ambery
c 44	20.6	0.8	48	24	ABK22464	Human ERG ambery
c 45	20.6	0.8	50	11	AAQ06172	Probe derived from
c 45	20.6	0.8	50	14	AAQ37565	RP10 derived BMP-6

ALIGNMENTS

RESULT 1
ABK65598/c
ID ABK65598 standard; DNA: 27 BP.

XX ABK65598;
XX 02-JUL-2002 (first entry)
XX Human gene specific PCR primer #686.
XX Primer; ss; DNA microarray; differential expression analysis; human.
XX Homo sapiens.
XX US6352829-B1.
XX 05-MAR-2002.
XX 05-JAN-1999; 99US-0225928.
XX 21-MAY-1997; 97US-0859998.
XX (CLON-) CLONTECH LAB INC.
XX Chenchik A, Johhadze G, Bibilashvilli R;
XX WPI; 2002-314699/35.
XX Producing sub-population of labeled nucleic acids, useful for analysing
XX differences in RNA profiles between several different physiological
XX sources, using set of distinct gene specific primers -

•
•
•
•
•

XX
DR WPI: 2000-013267/01.

Novel biallelic markers used to construct a high density disequilibrium map of the human genome

Claim 1: Page 535; 2745pp; English.

AZ26554 to AZ269578 represent human biallelic markers from the present invention, which contain a polymorphic base at position 21 of their nucleotide sequences. AZ26579 to AZ277440 represent amplification primers for the biallelic markers. The biallelic markers of the invention have a variety of uses: They can be used for high density mapping of the human genome, and in complex association studies and haplotyping studies which are useful in determining the genetic basis for disease states. Compositions and methods of the invention can also be useful for the identification of the targets for the development of pharmaceutical agents and diagnostic methods, as well as the characterisation of the differential efficacious responses to and side effects from pharmaceutical agents acting on a disease as well as other treatment.

N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and 3367, are not actually given a sequence in the sequence listing from the present invention.

Sequence 47 BP; 15 A; 4 C; 7 G; 21 T; 0 other;

Query Match 1.18; Score 26.6; DB 2

1.18; Score 26.6; DB 21; Length 47; Query Match

```

Query Match      1.1%; Score 20.0; DB 21; Length 47,
Best Local Similarity 78.0%; Pred. No. 2.1e+04;
Matches 32; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

```

1889 AGCATATTTTAGTTAGTACTAAATCTTAGTAAATGCTGA 1929

db 43 AACATATTTTAGTAATTGCTAAATACTTTGTAAACCATGA 3

RESULT 3

RESULT 3
ABK66597
ID ABK66597 standard: DNA; 26 BP.

AC ABK66597:

02-JUL-2002 (first entry)

Human gene specific PCR primer #685

XX human gene specific primer
KW primer; ss: DNA microarray; differential expression analysis; human.

XX
OS Homo sapiens.

XX
PN US6352829-B1.

XX
PD
05-MAR-2002.

XX.
05-JAN-1999;
PFXX
PR 21-MAY-1997:

XX
PA (CLON-) CLONTECH LAB INC.

Chenchik A. Jokhadze G. Bibilashvili R;

WPI: 2002-314699/35

producing sub-population of labeled nucleic acids, useful for analysing differences in RNA profiles between several different physiological sources, using set of distinct gene specific primers.

sources, using set of distinct gene spec

XX
PS Example 3: SEO ID No 685; 11pp; English.

XX

The invention relates to producing a sub-population of labeled nucleic acids (NAs) comprising contacting a NA sample from a physiological source, with a pool of 50 distinct gene specific primers under suitable

CC conditions to enzymatically generate sub-population of NAs, where
CC each gene specific primer has a sequence complementary to a distinct
CC mRNA, and each labeled NA is generated using a single gene specific
CC primer. The method is useful for producing a sub-population of labeled
CC NAs which is useful for analysing the differences in the RNA profiles
CC between several different physiological sources, where the method
CC comprises producing subpopulation of labeled NAs for the different
CC physiological sources, comprising the populations for each physiological
CC source to identify differences in the population, where the comparison
CC is preferably performed by hybridising the labeled NAs for each of the
CC distinct physiological sources to an array of probe NAs stably
CC associated with the surface of a substrate to produce a hybridisation
CC pattern for each of the sources, and comparing the patterns for each of
CC the sources, where differential gene expression assays are
CC utilised in differential expression analysis of diseased a normal
CC tissue e.g. neoplastic a normal tissue, or different tissue or
CC subissue types. The present sequence is a human gene specific PCR
CC primer used in the method of the invention.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from USPTO at
CC <http://wipo.seqdata.uspto.gov/sequence.html?DocID=635282981>.
XX

XX Sequence 26 BP; 9 A; 5 C; 9 G; 3 T; 0 other:

Query Match 1.14; Score 26; DB 24; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 507 GCACCAGGAGTCCCAAGGATTGAGA 532
DB 1 GCACCAGGAGTCCCAAGGATTGAGA 26

RESULT 4

ABL40869/c
ID ABL40868 standard; DNA; 34 BP.

XX ABL40868;

XX 03-JUL-2002 (first entry)

XX CREB cDNA amplifying primer #2.

XX Nucleic acid detection; transcription factor; cytostatic; reporter gene;
XX neuroprotective; cancer diagnosis; Li-Fraumeni syndrome; memory loss;
XX CREB; PCR primer; ss.

XX Synthetic.

XX WO200229043-A1.

XX 11-APR-2002.

XX 28-SEP-2001; 2001WO-JP08576.

XX 02-OCT-2000; 2000JP-0302100.

XX (HELI-) HELIX RES INST.

XX Oda T, Muramatsu M;

XX WPI; 2002-340106/37.

XX Identifying target gene of transcription factor for isolation in cells
XX with vectors expressing fused protein of transcription factor with its
XX activator and specific reporter gene, useful in cancer diagnosis and
XX therapy -

XX Example 1; Page 12; 32pp; Japanese.

XX The invention relates to a method of detecting the target gene of a
XX specific transcription factor. The method involves (a) supplying cells

CC containing a vector expressing a fused protein of the transcription
CC factor with an activator of this transcription factor and another vector
CC containing a reporter gene; (b) separating cells; and (c) comparing the
CC gene expression dose of the cells. The method is for identifying a target
CC gene of transcription factor for isolation, which is used for application
CC in cancer diagnosis and drug development for e.g. Li-Fraumeni syndrome
CC and long-term memory loss. With expression of the reporter gene as
CC indication, the identification and isolation can be efficiently carried
CC out because its enlarged expression dose in a cell is induced by the
CC transcription factor. Sequences ABL40867-874 represents primers used in
XX the course of the invention.

XX Sequence 34 BP; 10 A; 4 C; 10 G; 10 T; 0 other:

Query Match 1.04; Score 24; DB 24; Leng-h 34;
Best Local Similarity 100.0%; Pred. No. 6.8e+04;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1077 CTTTACTGCCACAAATTCAGATTAA 1100
DB 34 CTTTACTGCCACAAATTCAGATTAA 11

RESULT 5

ABL40870/c

ID ABL40870 standard; DNA; 34 BP.

XX ABL40870;

XX 03-JUL-2002 (first entry)

XX CREB cDNA amplifying primer #4.

XX Nucleic acid detection; transcription factor; cytostatic; reporter gene;
XX neuroprotective; cancer diagnosis; Li-Fraumeni syndrome; memory loss;
XX CREB; PCR primer; ss.

XX Synthetic.

XX WO200229043-A1.

XX 11-APR-2002.

XX 28-SEP-2001; 2001WO-JP08576.

XX 02-OCT-2000; 2000JP-0302100.

XX (HELI-) HELIX RES INST.

XX Oda T, Muramatsu M;

XX WPI; 2002-340106/37.

XX Identifying target gene of transcription factor for isolation in cells
XX with vectors expressing fused protein of transcription factor with its
XX activator and specific reporter gene, useful in cancer diagnosis and
XX therapy -

XX Example 1; Page 12; 32pp; Japanese.

XX The invention relates to a method of detecting the target gene of a
XX specific transcription factor. The method involves (a) supplying cells
XX containing a vector expressing a fused protein of the transcription
XX factor with an activator of this transcription factor and another vector
XX containing a reporter gene; (b) separating cells; and (c) comparing the
XX gene expression dose of the cells. The method is for identifying a target
XX gene of transcription factor for isolation, which is used for application
XX in cancer diagnosis and drug development for e.g. Li-Fraumeni syndrome
XX and long-term memory loss. With expression of the reporter gene as
XX indication, the identification and isolation can be efficiently carried
XX out because its enlarged expression dose in a cell is induced by the
XX transcription factor. Sequences ABL40867-874 represents primers used in
XX the course of the invention.

XX SQ Sequence 34 BP; 10 A; 4 C; 10 G; 10 T; 0 other:
 Query Match 1.0%; Score 24; DB 24; Length 34;
 Best Local Similarity 100.0%; Pred. No. 6.8e+04;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1077 CTTTACTGCCACAAATCAGATTAA 1100
 |||||
 DB 34 CTTTACTGCCACAAATCAGATTAA 11

RESULT 5
 AAV21495/C
 ID AAV21495 standard; DNA: 31 BP.
 AC AAV21495:
 XX
 DT 11-AUG-1998 (first entry)
 DE Plasmid pRSV-CREB341 3' CREB 283 primer.
 KW protein-protein interaction; disruption; binding protein; modulator;
 KW inhibitor; therapeutic; prophylactic; primer; ss.
 OS Synthetic.
 XX WO9813502-A2.
 PN
 XX
 PD 02-APR-1998.
 XX
 PF 26-SEP-1997; 97WO-US17276.
 XX
 PR 27-SEP-1996; 96US-0721730.
 XX
 PA (ICOS-); ICOS CORP.
 XX
 PI Goodman RH, Hoekstra MF;
 XX
 DR WPI: 1998-230711/20.

PT Identifying agents which disrupt protein/protein interactions -
 PT using host cells transformed with DNA to form transcriptional
 PT activating promoter which indirectly affects production of
 PT selectable marker

XX Example 1: Page 27; 96pp: English.

XX Oligonucleotides AAV21487 and AAV21503 are used in the construction of
 CC plasmids which are used in a method to identify agents which disrupt
 CC protein/protein interactions using a host cell which is transformed or
 CC transfected with DNA. The host cells are useful to demonstrate in vivo
 CC binding capacity of both known and suspected binding partner proteins
 CC in a recombinant system. The described expression system permits
 CC systematic analysis of the structure and function of a particular
 CC binding protein, thus permitting identification and/or synthesis of
 CC potential modulators of the physiological activity of the binding
 CC proteins. The system can be used to identify and improve molecules which
 CC are capable of inhibiting specific and general protein/protein
 CC interactions. Inhibitors identified by the methods can then be examined
 CC for utility in vivo as therapeutic and/or prophylactic medicaments for
 CC conditions associated with various protein/protein interactions. The
 CC system provides a sensitive assay and provides a positive signal when a
 CC protein/protein interaction is disrupted.

XX SQ Sequence 31 BP; 3 A; 10 C; 10 G; 8 T; 0 other:
 Query Match 1.0%; Score 23.4; DB 19; Length 31;
 Best Local Similarity 96.0%; Pred. No. 8.9e+04;
 Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 903 CAGCCTGCTGAAGACGACGACGAA 927
 |||||

DB 31 CAGCCTGCTGAAGACGACGACGAA 7

RESULT 7
 AAZ66915
 ID AAZ66915 standard; DNA: 47 BP.
 XX
 AC AAZ66915:
 XX
 DT 10-SEP-2001 (first entry)
 DE Human map-related biallelic marker SEQ ID NO:1262.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW diagnosis; single nucleotide polymorphism; SNP; ds.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT variation Replace(24,C)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 XX
 PN WO9954500-A2.
 XX
 XX 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB00822.
 XX
 PR 21-APR-1998; 98US-0082614.
 XX
 PR 23-NOV-1998; 98US-0109732.
 XX
 XX (GENT) GENSET.
 XX
 XX Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI: 2000-013267/01.

PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome -
 XX
 XX Claim 1: Page 499; 2745pp: English.

XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the
 CC invention have a variety of uses: they can be used for high density
 CC mapping of the human genome, and in complex association studies and
 CC haplotyping studies which are useful in determining the genetic basis
 CC for disease states. Compositions and methods of the invention can also
 CC be useful for the identification of the targets for the development of
 CC pharmaceutical agents and diagnostic methods, as well as the
 CC characterisation of the differential efficacious responses to and side
 CC effects from pharmaceutical agents acting on a disease as well as other
 CC treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
 CC and 3367, are not actually given a sequence in the Sequence Listing
 CC from the present invention.

XX SQ Sequence 47 BP; 23 A; 1 C; 8 G; 15 T; 0 other:
 Query Match 1.0%; Score 23.4; DB 21; Length 47;
 Best Local Similarity 73.2%; Pred. No. 9.8e+04;
 Matches 30; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 1364 AAGAAGTAAATTTCTTTACTTGTAAATTTGATCGGAGAAA 1404
 |||||
 DB 1 AAGAAGTAAATTTCTTTACTTGTAAATTTGATCGGAGAAA 41

```
RESULT 8
AAI77619/C
ID AAI77619 standard; DNA; 50 BP.
XX
AC AAI77619;
XX
DT 09-NOV-2001 (first entry)
XX
DE Human silent SNP containing nucleic acid SEQ:4560.
XX
KW Human; single nucleotide polymorphism; SNP; genome; gene therapy;
KW protein therapy; vaccine; probe; diagnostic assay; detection;
KW quantitation; restorative therapy; polymorphic; ds.
XX
OS Homo sapiens.
XX
PN W0200140521-A2.
XX
PD 07-JUN-2001.
XX
PF 30-NOV-2000; 2000WO-US32750.
XX
PR 30-NOV-1999; 99US-0158138.
XX
PR 29-NOV-2000; 2000US-0726173.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shinkets RA, Leach M;
XX
DR WPI: 2001-356160/37.
XX
XX Polymorphic nucleic acid sequences, useful in genetic testing and
PI therapy -
XX
PS Claim 1; Page 1906; 2653pp; English.
XX
CC AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide
CC sequences (I), which contain single nucleotide polymorphisms (SNPs).
CC AAM53114 to AAM53129 represent peptides related to human polymorphic
CC polynucleotide sequences. The sequences can be used in gene and protein
CC therapy, and in vaccine production. (I) and the polypeptides encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate expression of polymorphic polypeptides.
CC For example, (I) may be used to treat disorders by rectifying mutations
CC or deletions in a patient's genome that affect the activity of
CC polypeptides by expressing inactive proteins or to supplement the
CC patients own production of polypeptide. Additionally, (I) and its
CC complementary sequences may also be used as DNA probes in diagnostic
CC assays to detect and quantitate the presence of similar nucleic acids
CC in samples, and therefore which patients may be in need of restorative
CC therapy. The polypeptides encoded by (I) may be used as antigens in the
CC production of antibodies specific for polymorphic polypeptides. The
CC antibodies may also be used to down regulate expression and activity.
CC The antibodies may also be used as diagnostic agents for detecting the
CC presence of polymorphic polypeptides in samples.
XX
SQ Sequence 50 BP; 16 A; 4 C; 5 G; 25 T; 0 other;
Query Match 0.9%; Score 23; DB 22; Length 50;
Best Local Similarity 74.4%; Pred. No. 1.2e+05;
Matches 29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
QY 1160 AAGACAAATATACATTTTATTTCTAAACATTTCTTT 1198
II III III III III III III III III III
DB 39 AATGGAAGAAAAACCTGTATTTTCTAAATATTTCTTT 1
RESULT 9
AAL34381/C
ID AAL34381 standard; DNA; 50 BP.
XX
AC AAL34381;
XX
XX Human silent SNP containing nucleic acid SEQ:4560.
XX
DT 09-NOV-2001 (first entry)
XX
DE Human; single nucleotide polymorphism; SNP; genome; gene therapy;
KW protein therapy; vaccine; probe; diagnostic assay; detection;
KW quantitation; restorative therapy; polymorphic; ds.
XX
OS Homo sapiens.
XX
PN W0200140521-A2.
XX
PD 07-JUN-2001.
XX
PF 30-NOV-2000; 2000WO-US32750.
XX
PR 30-NOV-1999; 99US-0158138.
XX
PR 29-NOV-2000; 2000US-0726173.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shinkets RA, Leach M;
XX
DR WPI: 2001-356160/37.
XX
XX Polymorphic nucleic acid sequences, useful in genetic testing and
PI therapy -
XX
PS Claim 1; Page 1906; 2653pp; English.
XX
CC AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide
CC sequences (I), which contain single nucleotide polymorphisms (SNPs).
CC AAM53114 to AAM53129 represent peptides related to human polymorphic
CC polynucleotide sequences. The sequences can be used in gene and protein
CC therapy, and in vaccine production. (I) and the polypeptides encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate expression of polymorphic polypeptides.
CC For example, (I) may be used to treat disorders by rectifying mutations
CC or deletions in a patient's genome that affect the activity of
CC polypeptides by expressing inactive proteins or to supplement the
CC patients own production of polypeptide. Additionally, (I) and its
CC complementary sequences may also be used as DNA probes in diagnostic
CC assays to detect and quantitate the presence of similar nucleic acids
CC in samples, and therefore which patients may be in need of restorative
CC therapy. The polypeptides encoded by (I) may be used as antigens in the
CC production of antibodies specific for polymorphic polypeptides. The
CC antibodies may also be used to down regulate expression and activity.
CC The antibodies may also be used as diagnostic agents for detecting the
CC presence of polymorphic polypeptides in samples.
XX
SQ Sequence 50 BP; 16 A; 4 C; 5 G; 25 T; 0 other;
Query Match 0.9%; Score 23; DB 22; Length 50;
Best Local Similarity 74.4%; Pred. No. 1.2e+05;
Matches 29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
QY 1160 AAGACAAATATACATTTTATTTCTAAACATTTCTTT 1198
II III III III III III III III III III
DB 39 AATGGAAGAAAAACCTGTATTTTCTAAATATTTCTTT 1
RESULT 10
AAI73435
ID AAI73435 standard; DNA; 50 BP.
XX
AC AAI73435;
XX
XX Human silent SNP containing nucleic acid SEQ:376.
XX
DT 09-NOV-2001 (first entry)
XX
DE Human silent SNP containing nucleic acid SEQ:376.
XX
DE
```

```
DI 24-JAN-2002 (first entry)
XX
DE Human SNP oligonucleotide #7589.
XX
KW Immunosuppressive; immunostimulatory; anti-inflammatory; cytostatic;
KW neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
KW amyloid protein; angiotensin; apoptosis related protein; cadherin;
KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KW complement related protein; cytochrome; kinesin; cytokine; interferon;
KW interleukin; G-protein coupled receptor; thioesterase; inflammation;
KW multifactorial disease; autoimmune disease; infection;
KW nervous system disease; ss.
XX
OS Homo sapiens.
XX
PN W0200147944-A2.
XX
PD 05-JUL-2001.
XX
PF 28-DEC-2000; 2000WO-US35498.
XX
PR 28-DEC-1999; 99US-0173419.
XX
PR 27-DEC-2000; 2000US-0173419.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shinkets RA, Leach M;
XX
DR WPI: 2001-465210/50.
XX
XX Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
XX oncogenes and histones, useful for diagnosing and treating, e.g.
XX cancer, autoimmune diseases and infections -
XX
PS Claim 1; Page 3577; 4143pp; English.
XX
CC The present invention relates to oligonucleotides encoding polymorphic
CC variants of proteins related to amylases, amyloid proteins, angiotensin,
CC apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,
CC histones, kinases, colony stimulating factors, complement related
CC proteins, cytochromes, kinesins, cytokines, interferons, interleukins,
CC G-protein coupled receptors, and thioesterases. The present sequence is
CC one such oligonucleotide. The oligonucleotides and the peptides encoded
CC by them may be used in the prevention, diagnosis and treatment of
CC diseases associated with inappropriate expression of the proteins listed
CC above. Disorders that may be prevented, diagnosed and/or treated include
CC multifactorial diseases with a genetic component, such as autoimmune
CC diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,
CC systemic lupus erythematosus and Grave's disease), inflammation, cancer
CC (e.g. cancers of the bladder, brain, breast, colon and kidney,
CC leukaemia), diseases of the nervous system and an infection of pathogenic
CC organisms.
XX
SQ Sequence 50 BP; 18 A; 8 C; 11 G; 13 T; 0 other;
Query Match 0.9%; Score 22.6; DB 22; Length 50;
Best Local Similarity 68.9%; Pred. No. 1.5e+05;
Matches 31; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 2300 CAATATTTCGATTCATTCCTTACAAAACATTTTTCCTCTT 2344
II III III III III III III III III III
DB 49 CAATATTTCATTTGTTATGCTCCCAAAAATCTGGTAGAGCTCTT 5
RESULT 10
AAI73435
ID AAI73435 standard; DNA; 50 BP.
XX
AC AAI73435;
XX
XX Human silent SNP containing nucleic acid SEQ:376.
XX
DT 09-NOV-2001 (first entry)
XX
DE Human silent SNP containing nucleic acid SEQ:376.
XX
DE
```

XX Human; single nucleotide polymorphism; SNP; genome; gene therapy;
KW Protein therapy; vaccine; probe; diagnostic assay; detection;
KW Quantitation; restorative therapy; polymorphic; ds.
XX Homo sapiens.
XX WO200140521-A2.
XX 07-JUN-2001.
XX 30-NOV-2000; 2000WO-US32758.
XX 30-NOV-1999; 99US-0168138.
XX 29-NOV-2000; 2000US-0726173.
XX (CURA-) CURAGEN CORP.
XX PI Shimkets RA, Leach M;
XX WPI; 2001-356160/37.
XX Polymorphic nucleic acid sequences, useful in genetic testing and
XX therapy -
XX Claim 1; Page 169; 2653pp; English.
XX AA173060 to AA179867 represent isolated human polymorphic polynucleotide
XX sequences (I), which contain single nucleotide polymorphisms (SNPs).
XX CC AA53114 to AA53329 represent peptides related to human polymorphic
XX CC polynucleotide sequences, the sequences can be used in gene and protein
XX CC therapy, and in vaccine production. (I) and the polypeptides encoded by
XX CC them may be used in the prevention, diagnosis and treatment of diseases
XX CC associated with inappropriate expression of polymorphic polypeptides.
XX CC For example, (I) may be used to treat disorders by rectifying mutations
XX CC or deletions in a patient's genome that affect the activity of
XX CC polypeptides by expressing inactive proteins or to supplement the
XX CC patients own production of polypeptide. Additionally, (I) and its
XX CC complementary sequences may also be used as DNA probes in diagnostic
XX CC assays to detect and quantitate the presence of similar nucleic acids
XX CC in samples, and therefore which patients may be in need of restorative
XX CC therapy. The polypeptides encoded by (I) may be used as antigens in the
XX CC production of antibodies specific for polymorphic polypeptides. The
XX CC antibodies may also be used to down regulate expression and activity.
XX CC The antibodies may also be used as diagnostic agents for detecting the
XX CC presence of polymorphic polypeptides in samples.
XX SQ Sequence 50 BP; 15 A; 3 C; 6 G; 26 T; 0 other;
Query Match 0.9%; Score 22.4; DB 22; Length 50;
Best Local Similarity 66.7%; Pred. No. 1.6e+05;
Matches 32; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
OY 2310 ATTGTCATCTTACAAACATTTTGTCTCTCTGTAAGAGTAG 2357
||| | ||||| |||| | ||| | || | |||| |
Db 1 ATTTTCTTAAACAAATTTTGTCTCTCTCTGTAAGAGTAG 48
RESULT 11
AA17082/C
ID AA17082 standard; DNA; 45 BP.
XX AC AA17082;
XX 02-JUL-1996 (first entry)
XX DE Primer ENDO.1, amplifies RNase P conjugate.
XX KW Primer; RNase P conjugate; amplification; PCR; Endo.P1; Endo.P2;
KW sequence specific cleavage; gene therapy; pathogenic RNA;
XX viral transcript; RNA genome; disease-causing mRNA; oncogene; ss.
XX OS Synthetic.

XX WO9532283-A1.
XX 30-NOV-1995.
XX 23-MAY-1995; 95WO-US06519.
XX 23-MAY-1994; 94US-0247776.
XX (INDV) UNIV INDIANA FOUND.
XX Frank DH, Harris ME, Pace NR;
XX WPI; 1996-020578/02.
XX RNase P RNA conjugates function as sequence-specific endonuclease(s)
XX - useful for gene therapy and study cf, e.g. viral activity in
XX vitro.
XX Example; Page 14; 49pp; English.
XX The sequences given in AA17078-84 are primers which were used in the
XX construction of the RNase P conjugates of the invention. These
XX primers amplify the Endo.P1 and Endo.P2 genes. The conjugate also
XX includes an oligonucleotide which includes a predetermined sequence
XX complementary to and available for hybridization with a nucleotide
XX sequence of the target sequence. The conjugates cause sequence
XX specific cleavage of the target oligonucleotide. The conjugates are
XX useful in gene therapy for the selective degradation of pathogenic
XX RNA's such as viral transcripts or RNA genomes, or of disease-
XX causing mRNA's such as products of oncogenes.
XX SQ Sequence 45 BP; 13 A; 9 C; 9 G; 14 T; 0 other;
Query Match 0.9%; Score 22.2; DB 17; Length 45;
Best Local Similarity 77.1%; Pred. No. 1.7e+05;
Matches 27; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
OY 1823 TAACCACTGAACGACAAAGCATGTGTTTGAATT 1857
||||| ||||| | | | ||||| |||||
Db 38 TAACCACTGAACGACGATGAGTCGTATTAGAATT 4
RESULT 12
ABL40867
ID ABL40867 standard; DNA; 33 BP.
XX AC ABL40867;
XX 03-JUL-2002 (first entry)
XX DE CREB cDNA amplifying primer #1.
XX KW Nucleic acid detection; transcription factor; cytostatic; reporter gene;
KW neuroprotective; cancer diagnosis; Li-Fraumeni syndrome; memory loss;
KW CREB; PCR primer; ss.
XX OS Synthetic.
XX WO200229043-A1.
XX 11-APR-2002.
XX 28-SEP-2001; 2001WO-JP08576.
XX 02-OCT-2000; 2000JP-0302100.
XX (HELI-) HELIX RES INST.
XX Oda T, Muramatsu M;
XX NFI; 2002-340106/37.

PT Identifying target gene of transcription factor for isolation in cells
 PT with vectors expressing fused protein of transcription factor with its
 PT activator and specific reporter gene, useful in cancer diagnosis and
 PT therapy -
 XX
 PS Example 1: Page 12: 32pp: Japanese.
 CC The invention relates to a method of detecting the target gene of a
 CC specific transcription factor. The method involves (a) supplying cells
 CC containing a vector expressing a fused protein of the transcription
 CC factor with an activator of this transcription factor and another vector
 CC containing a reporter gene; (b) separating cells; and (c) comparing the
 CC gene expression dose of the cells. The method is for identifying a target
 CC gene of transcription factor for isolation, which is used for application
 CC in cancer diagnosis and drug development for e.g. Li-Fraumeni syndrome
 CC and long-term memory loss. With expression of the reporter gene as
 CC indication, the identification and isolation can be efficiently carried
 CC out because its enlarged expression dose in a cell is induced by the
 CC transcription factor. Sequences ABL40867-874 represents primers used in
 CC the course of the invention.
 XX
 SQ Sequence 33 BP; 10 A; 6 C; 8 G; 9 T; 0 other;
 Query Match 0.94; Score 22; DB 24; Length 33;
 Best Local Similarity 83.3%; Pred. No. 1.8e+05;
 Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 110 TACTAATGACCATGGATCTGGAGCCGA 139
 DB 3 TGAATTCATGACCATGGATCTGGAGCAGA 32
 RESULT 13
 ABL01753/c
 ID ABL01753 standard; DNA; 46 BP.
 XX
 AC ABL01753;
 XX
 DT 18-MAR-2002 (first entry)
 XX
 DE Human MSH2 (hMSH2) Intronic sequence SEQ ID NO:106.
 XX
 KW Human; MLH1; MSH2; hMLH1; hMSH2; variant gene; diagnosis; HNPCC;
 KW hereditary non-polyposis colorectal cancer; ds.
 XX
 OS Homo sapiens.
 XX
 PN US2001044936-A1.
 XX
 PD 22-NOV-2001.
 XX
 PF 22-OCT-1999; 99US-0426548.
 XX
 PR 22-OCT-1998; 98US-1051E0P.
 XX
 PA (ROBB/) ROBBINS D.
 PA (LING/) LIN-GOERKE J L.
 PA (LING/) LING J C.
 XX
 PI Robbins D, Lin-Goerke JL, Ling JC;
 XX
 DR WPI; 2002-105577/14.
 XX
 PT New variants of the human MLH1 and MSH2 genes for diagnosing or
 PT determining a predisposition for hereditary non-polyposis colorectal
 PT cancer -
 XX
 PS Disclosure; Page 4; 38pp: English.
 CC The present invention describes a variant human MLH1 or MSH2 gene.
 CC Also described are: (1) a method for diagnosing or predicting
 CC susceptibility to hereditary non-polyposis colorectal cancer (HNPCC),
 CC comprising screening a DNA sample for the variant MLH1 or MSH2 gene

CC where presence of the variant indicates presence of, or susceptibility
 CC to HNPCC; (2) a method of identifying mutants in splice donor or
 CC acceptor sites of a human MLH1 gene, comprising sequencing splice donor
 CC or acceptor sites of the gene with intronic primers for the human MLH1
 CC gene and analysing the sequence to identify any mutants; (3) a method of
 CC identifying mutants in splice donor or acceptor sites of a human MSH2
 CC gene, comprising sequencing splice donor or acceptor sites of the gene
 CC with intronic primers for the human MSH2 gene and analysing the sequence
 CC to identify any mutants; and (4) a transgenic model system for
 CC colorectal cancer comprising cells expressing the variant MLH1 or MSH2
 CC gene. The hMLH1 and hMSH2 variants are used to diagnose or determine a
 CC patient's susceptibility to hereditary non-polyposis colorectal cancer.
 CC ABL01648 to ABL01745 and ABL01746 to ABL01831 represent hMLH1 and hMSH2
 CC gene fragments from the present invention. ABL01832 to ABL01839
 CC represent mutagenic primers used in the exemplification of the present
 CC invention.
 XX
 SQ Sequence 46 BP; 14 A; 5 C; 4 G; 23 T; 0 other;
 Query Match 0.9%; Score 22; DB 24; Length 46;
 Best Local Similarity 73.7%; Pred. No. 1.9e+05;
 Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
 QY 1870 AAGTAATTAAGTACAAAGCATATTATTAGTAGTAC 1907
 DB 43 AAAAAAAAAAAGTACATTACATTTGAGATTATAC 5
 RESULT 14
 AAI71996/c
 ID AAI71996 standard; DNA; 47 BP.
 XX
 AC AAI71996;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE VCP1579 primer HIVP100.
 XX
 KW Immunisation; Human Immunodeficiency Virus; HIV; envelope glycoprotein;
 KW priming antigen; booster antigen; attenuated; viral vector; primer; PCR;
 KW long terminal repeat; LTR; HIV-1; polymerase chain reaction; amplify; ss.
 XX
 OS Synthetic.
 XX
 PN WO200182962-A2.
 XX
 PD 08-NOV-2001.
 XX
 PF 25-APR-2001; 2001WO-CA00577.
 XX
 PR 27-APR-2000; 2000US-200011P.
 XX
 PA (AVET) AVENTIS PASTEUR LTD.
 XX
 PI Rovinski B, Tartaglia J, Cao S, Persson R, Klein MH;
 XX
 DR WPI; 2002-034490/04.
 XX
 PT Immunizing against Human Immunodeficiency Virus (HIV) using primary and
 PT booster antigens -
 XX
 PS Example 4; Page 16; 38pp; English.
 XX
 CC The sequences given in AAI71986-97 are primers which were used in
 CC the production of the recombinant poxvirus, VCP1579. VCP1579 contains
 CC the HIV-1 gag and protease genes derived from the HIV-1 isolate IIB,
 CC the gp120 envelope sequences derived from the HIV-1 Bx08 isolate, and
 CC sequences encoding a polypeptide encompassing the known human
 CC cytotoxic T lymphocytes (CTL) epitopes from HIV-1 Nef and Pol. VCP1579
 CC may be used to immunise against Human Immunodeficiency Virus (HIV). The
 CC method of the invention for immunising against HIV infection uses priming
 CC (DNA encoding an envelope glycoprotein of a primary HIV-1 isolate) and
 CC booster antigens (non-infectious, non-replicating immunogenic HIV-1-like

Search completed: March 9, 2003, 19:08:20
Job time : 513 secs


```

1  TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
2  TITLE OF INVENTION: EXPRESSION
3  NUMBER OF SEQUENCES: 1375
4  CORRESPONDENCE ADDRESS:
5  ADDRESSEE: Fish & Richardson, P.C.
6  STREET: 2200 Sand Hill Road, Suite 100
7  CITY: Menlo Park
8  STATE: CA
9  COUNTRY: US
10 ZIP: 94025
11 COMPUTER READABLE FORM:
12 MEDIUM TYPE: Diskette
13 COMPUTER: IBM Compatible
14 OPERATING SYSTEM: Windows95
15 SOFTWARE: FASTSEQ for Windows Version 2.0
16 CURRENT APPLICATION DATA:
17 APPLICATION NUMBER: US/08/859,998
18 FILING DATE: 21-MAY-1997
19 CLASSIFICATION: 435
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER:
22 FILING DATE:
23 ATTORNEY/AGENT INFORMATION:
24 NAME: Field, Bret E.
25 REGISTRATION NUMBER: 37,620
26 REFERENCE/DOCKET NUMBER: 09096/002001
27 TELECOMMUNICATION INFORMATION:
28 TELEPHONE: 415-322-5070
29 TELEFAX: 415-854-0875
30 INFORMATION FOR SEQ ID NO: 685:
31 SEQUENCE CHARACTERISTICS:
32 LENGTH: 26 base pairs
33 TYPE: nucleic acid
34 STRANDEDNESS: single
35 TOPOLOGY: linear
36 MOLECULE TYPE: DNA
37 OTHER INFORMATION: oligonucleotide primer
38
39 US-08-859-998-685
40
41 Query Match 1.1%; Score 26; DB 2; Length 26;
42 Best Local Similarity 100.0%; Pred. No. 7e+02;
43 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
44
45 QY 507 GCACCAGGAGTCCCAAGGATTGAAGA 532
46 11111111111111111111111111111111
47 DB 1 GCACCAGGAGTCCCAAGGATTGAAGA 26
48
49 RESULT 4
50 US-09-225-928-685
51 Sequence 685, Application US/09225928
52 Patent No. 6352829
53 GENERAL INFORMATION:
54 APPLICANT: Chenchik, Alex
55 Tokhadze, George
56 Bibilashvili, Robert
57 TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
58 EXPRESSION
59 NUMBER OF SEQUENCES: 1375
60 CORRESPONDENCE ADDRESS:
61 ADDRESSEE: Fish & Richardson, P.C.
62 STREET: 2200 Sand Hill Road, Suite 100
63 CITY: Menlo Park
64 STATE: CA
65 COUNTRY: US
66 ZIP: 94025
67 COMPUTER READABLE FORM:
68 MEDIUM TYPE: Diskette
69 COMPUTER: IBM Compatible
70 OPERATING SYSTEM: Windows95
71 SOFTWARE: FASTSEQ for Windows Version 2.0
72 CURRENT APPLICATION DATA:

```

APPLICATION NUMBER: US/09/225,928
 FILING DATE: 05-Jan-1999
 CLASSIFICATION: <Unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/859,998
 FILING DATE: 21-May-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Field, Bret E.
 REGISTRATION NUMBER: 37,620
 REFERENCE/DOCKET NUMBER: 09096/002001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-854-0875
 TELEFAX: 415-854-0875
 INFORMATION FOR SEQ ID NO: 685:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 26 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA
 FEATURE:
 OTHER INFORMATION: oligonucleotide primer
 SEQUENCE DESCRIPTION: SEQ ID NO: 685:
 US-09-225-928-685

Query Match 1.1%; Score 26; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 GCACCAGAGTGCACCAAGATTGAAGA 532
 |||||
 DB 1 GCACCAGAGTGCACCAAGATTGAAGA 26

RESULT 5
 US-08-881-094-33
 Sequence 33, Application US/08881094A
 Patent No. 6022739
 GENERAL INFORMATION:
 APPLICANT: Ryan, Clarence A.
 APPLICANT: Pearce, Gregory L.
 APPLICANT: McGurl, Barry F.
 TITLE OF INVENTION: Systemin
 FILE REFERENCE: 7555-000001CPB
 CURRENT APPLICATION NUMBER: US/08/881,094A
 CURRENT FILING DATE: 1997-07-09
 EARLIER APPLICATION NUMBER: 08/308,887
 EARLIER FILING DATE: 1994-09-19
 EARLIER APPLICATION NUMBER: PCT/US93/02428
 EARLIER FILING DATE: 1993-03-18
 EARLIER APPLICATION NUMBER: 07/885,412
 EARLIER FILING DATE: 1992-03-19
 EARLIER APPLICATION NUMBER: 07/528,956
 EARLIER FILING DATE: 1990-05-25
 EARLIER APPLICATION NUMBER: PCT/US91/03685
 EARLIER FILING DATE: 1991-05-24
 NUMBER OF SEQ ID NOS: 43
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 33
 LENGTH: 40
 TYPE: DNA
 ORGANISM: Lycopersicon esculentum
 US-08-881-094-33

Query Match 0.9%; Score 21; DB 3; Length 40;
 Best Local Similarity 73.0%; Pred. No. 1.5e+04;
 Matches 27; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 503 TGATGCACGAGTGCACCAAGATTGAAGAAGAGAG 539
 |||||
 DB 4 TCATACACAGAAATACCAAGATGGAACATGAGAG 40

RESULT 6
 US-07-977-696C-60
 Sequence 60, Application US/07977696C
 Patent No. 572852
 GENERAL INFORMATION:
 APPLICANT: do Couto, Fernando J.R.
 APPLICANT: Ceriani Dr., Roberto L.
 APPLICANT: Peterson Dr., Jerry A.
 APPLICANT: Padlan Dr., Eduardo A.
 TITLE OF INVENTION: Analogue Peptides with Specificity
 TITLE OF INVENTION: for Carcinomas and Kit and Diagnostic Vaccination
 TITLE OF INVENTION: and Therapeutic Methods.
 NUMBER OF SEQUENCES: 81
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: PRETTY, SCHROEDER & POPLAWSKI
 STREET: 444 South Flower Street, Suite 2000
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/977.696C
 FILING DATE: 11-16-92
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Anzel Ph.D., Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE/DOCKET NUMBER: P66 38227
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (510) 748-6868
 TELEFAX: (510) 748-6868
 TELEX: n.a.
 INFORMATION FOR SEQ ID NO: 60:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 50 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-07-977-696C-60

Query Match 0.9%; Score 21; DB 1; Length 50;
 Best Local Similarity 73.0%; Pred. No. 1.6e+04;
 Matches 27; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Cy 953 CAGGGAAGCAGCTCGAGACTGCTGAGAAAGAGAAA 989
 |||||
 Db 14 CAGGGAAGCGCTTGAGTGGTGTCTGAAATAGAAA 50

RESULT 7
 US-08-129-93CB-60
 Sequence 60, Application US/08129930B
 Patent No. 5804167
 GENERAL INFORMATION:
 APPLICANT: do Couto Dr., Fernando J.R.
 APPLICANT: Ceriani Dr., Roberto L.
 APPLICANT: Peterson Dr., Jerry A.
 APPLICANT: Padlan Dr., Eduardo A.
 TITLE OF INVENTION: Analogue Peptides with Broad
 TITLE OF INVENTION: Carcinoma Specificity, and Kit and
 TITLE OF INVENTION: Diagnostic Vaccination and
 TITLE OF INVENTION: Therapeutic Methods
 NUMBER OF SEQUENCES: 96
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: V. AMZEL & ASSOC.
 STREET: 2055 No. 5804187th Broadway, Suite 201
 CITY: Walnut Creek


```
Query Match      0.9%; Score 21; DB 4; Length 50;
Best Local Similarity 73.0%; Pred. No. 1.6e+04;
Matches 27; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
```

RESULT 9
US-09-387-800-5/c
Sequence 5, Application US/09387800
Patent No. 6280972
GENERAL INFORMATION:
APPLICANT: YASUEDA, Hisashi
TITLE OF INVENTION: NOVEL ACTIVATOR FOR ALCOHOL DEHYDROGENASE AND GENE
TITLE OF INVENTION: THEREOF
FILE REFERENCE: 0010-1036-0

```

1 CURRENT FILING DATE: 1999-09-01
2 EARL-ER APPLICATION NUMBER: JP 10-248297
3 EARL-ER FILING DATE: 1998-09-02
4 NUMBER OF SEQ ID NOS: 7
5 SOFTWARE: PatentIn Ver. 2.1
6 SEQ ID NO 5
7 LENGTH: 43
8 TYPE: DNA
9 ORGANISM: Artificial Sequence
10 FEATURE:
11 OTHER INFORMATION: Description of Artificial Sequence:BS-YOKG1-1
12 US-09-387-800-5

```

```

RESULT 10
US-09-476-256-29
; Sequence 29, Application US/09476256
; Patent No. 6228592
; GENERAL INFORMATION:
; APPLICANT: Laboratory of Molecular Biophotonics
; TITLE OF INVENTION: Nucleic Acid Detection in Cytoplasm
; FILE REFERENCE: BBP99-02
; CURRENT APPLICATION NUMBER: US/09/476,256
; CURRENT FILING DATE: 1999-12-30
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 29
; LENGTH: 40
; TYPE: DNA

```

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: probe
US-09-476-256-29

Query Match 0.8% Score 20.6; DB 4; Length 40;
Best Local Similarity 74.3%; Pred. No. 1.9e+04;
Matches 26; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1329 GAAGAGACTCTGCTTTTCAACCCACCCCTCCCTC 1363
DB 2 GATGAGAAGTCTGCTTTGCCCCCCCCCCCCCCCC 36

RESULT 11
US-09-349-644-13
Sequence 13, Application US/09349644A
Patent No. 6303340

GENERAL INFORMATION:
APPLICANT: Pollitt, Stephen N.
APPLICANT: Buckley, Douglas I.
APPLICANT: Statish, Peter A.
APPLICANT: Hartman, Tawmar E.
TITLE OF INVENTION: METHOD FOR PRODUCING A PEPTIDE WITH A PI
FILE REFERENCE: SCIOS.019A
CURRENT APPLICATION NUMBER: US/09/349.644A
EARLIER FILING DATE: 1999-07-08
EARLIER FILING DATE: 1998-07-10
NUMBER OF SEQ ID NOS: 14
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 13
LENGTH: 44
TYPE: DNA
ORGANISM: E. coli
US-09-349-644-13

Query Match 0.8% Score 20.6; DB 4; Length 44;
Best Local Similarity 74.3%; Pred. No. 2e+04;
Matches 26; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2112 TATATTTCTTTTGAATGTTACATGTAGAAAA 2146
DB 3 TTTTATTTTATGTTATGTTACATGAGAAAA 37

RESULT 12
US-09-980-071-21/c
Sequence 21 Application US/09980071
Patent No. 5914318

GENERAL INFORMATION:
APPLICANT: Baum, James A.
APPLICANT: Gilmer, Amy Jelen
APPLICANT: Mettus, Anne-Marie Light
TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING
TITLE OF INVENTION: LEPIDOPTERAN-ACTIVE-DELTA-ENDOTOXINS
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/980.071
FILING DATE: Concurrently Herewith

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/757,536
FILING DATE: 27-NOV-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kitchell, Barbara S.
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MECO:206
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-980-071-21

Query Match 0.8% Score 20.6; DB 2; Length 50;
Best Local Similarity 67.4%; Pred. No. 2.1e+04;
Matches 29; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1332 GAGACTTCGCTTTTCAACCCACCCCTCCCTCAAGAGATATA 1374
DB 50 GACATTATGCTGTCTCAACCCCATGCTCTCCAAAAATTACA 8

RESULT 13
US-08-757-536-21/c
Sequence 21 Application US/08757536
Patent No. 5942664

GENERAL INFORMATION:
APPLICANT: Baum, James A.
APPLICANT: Gilmer, Amy Jelen
APPLICANT: Mettus, Anne-Marie Light
TITLE OF INVENTION: Bacillus thuringiensis CryIC
TITLE OF INVENTION: Making CryIC Mutants
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White and Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: TX
COUNTRY: USA
ZIP: 77210-4433
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/757.536
FILING DATE: CONCURRENTLY HEREWITH
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Kitchell, Barbara
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MOBT:023
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-757-536-21

Query Match 0.8% Score 20.6; DB 2; Length 50;
Best Local Similarity 67.4%; Pred. No. 2.1e+04;

NUMBER OF SEQUENCES: 57

Search completed: March 9, 2003, 21:46:21
Job time : 106 secs

OM nucleic - nucleic search, using sv model

Run on: March 9, 2003, 19:08:27 ; Search time 197 Seconds
(without alignments)
8120.180 Million cell updates/sec

Title: US-09-973-827-3
Perfect score: 2454
Sequence: 1 cgcgcggagggtgtgttg.....tcgtattgtgtatcat 2454

Scoring table: IDENTITY NUC
Gapop 10.0 , Capext 1.0

Searched: 478924 seqs, 33359956 residues

Total number of hits satisfying chosen parameters: 261222

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 3: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 4: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 6: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	22	0.9	46	10	US-09-426-548-106
C 2	22	0.9	47	10	US-09-842-883-13
C 3	22	0.9	48	10	US-09-842-883-14
C 4	20.8	0.8	45	10	US-09-838-386-17
C 5	20.8	0.8	45	10	US-09-838-386-18
C 6	20.4	0.8	43	9	US-10-027-806-92
C 7	20.4	0.8	43	9	US-10-034-623-92
C 8	20.4	0.8	47	9	US-09-853-526-206
C 9	20.4	0.8	47	10	US-09-901-484A-206
C 10	20.2	0.8	44	9	US-10-079-623-71
C 11	20	0.8	46	10	US-09-827-289-22
C 12	20	0.8	46	9	US-09-864-785-3523
C 13	19.8	0.8	41	10	US-09-921-402-28
C 14	19.8	0.8	43	10	US-09-921-388-18
C 15	19.8	0.8	46	9	US-09-263-959-486
C 16	19.8	0.8	46	9	US-09-792-793A-48
C 17	19.8	0.8	46	9	US-09-825-805-55
C 18	19.6	0.8	36	10	US-09-062-113-50
C 19	19.6	0.8	45	10	US-09-910-059-127

Sequence 3014, Ap
Sequence 1089, Ap
Sequence 3448, Ap
Sequence 3573, Ap
Sequence 3399, App
Sequence 9, Appl
Sequence 25, Appl
Sequence 3078, Ap
Sequence 3557, Ap
Sequence 2759, Ap
Sequence 8, Appl
Sequence 283, App
Sequence 50, Appl
Sequence 25, Appl
Sequence 1, Appl
Sequence 3061, Ap
Sequence 3146, Ap
Sequence 3552, Ap
Sequence 13, Appl
Sequence 3205, Ap
Sequence 3213, Ap
Sequence 3295, Ap
Sequence 3321, Ap
Sequence 3574, Ap
Sequence 3614, Ap

20 19.6 0.8 48 9 US-09-864-785-3014
21 19.4 0.8 38 9 US-09-864-785-1089
22 19.4 0.8 48 9 US-09-864-785-3448
23 19.4 0.8 48 9 US-09-864-785-3573
24 19 0.8 31 10 US-09-801-274-3399
25 19 0.8 35 9 US-09-904-5374-3399
26 19 0.8 46 10 US-09-827-289-26
27 19 0.8 48 9 US-09-864-785-3078
28 19 0.8 48 9 US-09-864-785-3557
29 19 0.8 50 10 US-09-783-550-2759
30 18.8 0.8 42 10 US-09-904-380-8
31 18.8 0.8 47 9 US-09-853-526-283
32 18.8 0.8 47 10 US-09-901-484A-283
33 18.8 0.8 48 9 US-09-825-805-50
34 18.6 0.8 33 10 US-09-971-611-25
35 18.6 0.8 45 9 US-10-043-415-1
36 18.6 0.8 48 9 US-09-864-785-3061
37 18.6 0.8 48 9 US-09-864-785-3146
38 18.6 0.8 48 9 US-09-864-785-3552
39 18.6 0.8 50 9 US-09-923-070A-13
40 18.4 0.7 48 9 US-09-864-785-3205
41 18.4 0.7 48 9 US-09-864-785-3215
42 18.4 0.7 48 9 US-09-864-785-3295
43 18.4 0.7 48 9 US-09-864-785-3322
44 18.4 0.7 48 9 US-09-864-785-3574
45 18.4 0.7 48 9 US-09-864-785-3614

ALIGNMENTS

RESULT 1
US-09-426-548-106/c
; Sequence 106, Application US/09426548
; Patent No. US20010044936A1
; GENERAL INFORMATION:
; APPLICANT: Robbins, David
; APPLICANT: Lin-Goerke, Jullia L.
; APPLICANT: Ling, Jessica
; TITLE OF INVENTION: No. US20010044936A1el Mutations in Human MLH1 and MSH2 Gene:
; TITLE OF INVENTION: Diagnosing Colorectal Cancer
; FILE REFERENCE: DEX-0034
; CURRENT APPLICATION NUMBER: US/09/426,548
; CURRENT FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 106
; LENGTH: 46
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-426-548-106

Query Match 0.9%; Score 22; DB 10; Length 46;
Best Local Similarity 73.7%; Pred. No. 5,9e+04;
Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
QY 1870 AAAGTAATAAGTACAAAGCATATTTAGTAGTAGTAC 1907
DB 43 AAAAAAAAAAAGTACATACAGATTGAGATATTAC 6

RESULT 2
US-09-842-883-13/c
; Sequence 13, Application US/09842883
; Patent No. US20020051770A1
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Tartaglia, James
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H.
; TITLE OF INVENTION: IMMUNIZING AGAINST HIV INFECTION
; FILE REFERENCE: 1038-1142 MIS

; CURRENT APPLICATION NUMBER: US/09/842,883
; CURRENT FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: 60/200,011
; PRIOR FILING DATE: 2000-04-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 13
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-09-842-883-13

Query Match 0.9%; Score 22; DB 10; Length 47;
Best Local Similarity 73.7%; Pred. No. 5e+04;
Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 968 AGAGTCTCTAGAGAGAGAGATATGCAATGTT 1005
DB 47 AGAGTCTCTAGAGAGAGAGATATGCAATGTT 10

RESULT 3

US-09-842-883-14
; Sequence 14, Application US/09842883
; Patent No. US20020051770A1
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Tartaglia, James
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H.
; TITLE OF INVENTION: IMMUNIZING AGAINST HIV INFECTION
; FILE REFERENCE: 1038-1142 MIS
; CURRENT APPLICATION NUMBER: US/09/842,883
; CURRENT FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: 60/200,011
; PRIOR FILING DATE: 2000-04-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 14
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-09-842-883-14

Query Match 0.9%; Score 22; DB 10; Length 48;
Best Local Similarity 73.7%; Pred. No. 6e+04;
Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 968 AGAGTCTCTAGAGAGAGAGATATGCAATGTT 1005
DB 1 AGAGTCTCTAGAGAGAGAGATATGCAATGTT 38

RESULT 4

US-09-838-386-17
; Sequence 17, Application US/09838386
; Patent No. US20010055756A1
; GENERAL INFORMATION:
; APPLICANT: Pellerin, Charles
; APPLICANT: Kukolj, George
; TITLE OF INVENTION: Internal De No. US20010055756A1o Initiation Sites of the HCV NS5B
; FILE REFERENCE: 1011.2180001
; CURRENT APPLICATION NUMBER: US/09/838,386
; CURRENT FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 60/198,793
; PRIOR FILING DATE: 2000-04-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 17
; LENGTH: 45
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: oligonucleotide
US-09-838-386-17

Query Match 0.8%; Score 20.8; DB 10; Length 45;
Best Local Similarity 70.0%; Pred. No. 1.1e+05;
Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1168 AATAACATTTTATTTCTAACAATTTCTTTTCTATG 1207
DB 3 AATAGGCCATTTTCTTTTCTTTTCTTTTCTTTG 42

RESULT 5

US-09-838-386-18/c
; Sequence 18, Application US/09838386
; Patent No. US20010055756A1
; GENERAL INFORMATION:
; APPLICANT: Pellerin, Charles
; APPLICANT: Kukolj, George
; TITLE OF INVENTION: Internal De No. US20010055756A1o Initiation Sites of the HCV
; FILE REFERENCE: 1011.2180001
; CURRENT APPLICATION NUMBER: US/09/838,386
; CURRENT FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 60/198,793
; PRIOR FILING DATE: 2000-04-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 18
; LENGTH: 45
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: oligonucleotide
US-09-838-386-18

Query Match 0.8%; Score 20.8; DB 10; Length 45;
Best Local Similarity 70.0%; Pred. No. 1.1e+05;
Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1168 AATAACATTTTATTTCTAACAATTTCTTTTCTATG 1207
DB 43 AATAGGCCATTTTCTTTTCTTTTCTTTTCTTTG 4

RESULT 6

US-10-027-806-92/c
; Sequence 92, Application US/10027806
; Patent No. US20020160476A1
; GENERAL INFORMATION:
; APPLICANT: Swanson, Ronald V.
; APPLICANT: Feldman, Robert A.
; APPLICANT: Schleper, Christa
; TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS FROM CENARCHAEUM SYMBIOSUM
; FILE REFERENCE: DCORP 002A
; CURRENT APPLICATION NUMBER: US/10/027,806
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/408,020
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-09-29
; NUMBER OF SEQ ID NOS: 123
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 92
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Cenarchaeum symbiosum
; FEATURE:
; NAME/KEY: TATA_signal
; LOCATION: (11)...(16)
US-10-027-806-92

```
Query Match      0.8%; Score 20.4; DB 9; Length 43;
Best Local Similarity 71.1%; Pred. No. 1.3e+05;
Matches 27; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 90 GCAGGAGCTGTACACCGGTAACTAAATGACCATGGA 127
DB 39 GCAGCAGGTGTACCCCGGTAAATTAATGAGCCGGA 2

RESULT 7
US-10-034-623-92/c
; Sequence 92, Application US/10034623
; Publication No. US20020198365A1
; GENERAL INFORMATION:
; APPLICANT: Swanson, Ronald V.
; APPLICANT: Feldman, Robert A.
; APPLICANT: Schleper, Christa
; FILE OF INVENTION: NUCLEIC ACIDS AND PROTEINS FROM CENARCHAEUM SYMBIOSUM
; TITLE REFERENCE: DEORP.002A
; CURRENT APPLICATION NUMBER: US/10/034,623
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 09/408,020
; PRIOR FILING DATE: 1999-09-29
; PRIOR APPLICATION NUMBER: 60/102,294
; PRIOR FILING DATE: 1998-09-29
; NUMBER OF SEQ ID NOS: 123
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 92
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Cenarchaeum symbiosum
; FEATURE:
; NAME/KEY: TATA_signal
; LOCATION: (11)...(16)
US-10-034-623-92

Query Match      0.8%; Score 20.4; DB 9; Length 43;
Best Local Similarity 71.1%; Pred. No. 1.3e+05;
Matches 27; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 90 GCAGGAGCTGTACACCGGTAACTAAATGACCATGGA 127
DB 39 GCAGCAGGTGTACCCCGGTAAATTAATGAGCCGGA 2

RESULT 8
US-09-853-526-206
; Sequence 206, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilyu, Chumakov
; APPLICANT: Bougueleret, Lydie
; FILE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSER.18CPCP
; CURRENT APPLICATION NUMBER: US/09/853,526
; CURRENT FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 09/218,207
; PRIOR FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 206
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: (1)...(47)
; OTHER INFORMATION: polymorphic fragment 4-50-323
; NAME/KEY: allele
; LOCATION: (24)...(24)
; OTHER INFORMATION: polymorphic base C
; NAME/KEY: primer_bind
; LOCATION: (1)...(23)
; OTHER INFORMATION: potential microsequencing oligo 4-50-323.mis1
; NAME/KEY: primer_bind
; LOCATION: (25)...(47)
; OTHER INFORMATION: complement potential microsequencing oligo 4-50-323.mis2
US-09-901-484A-206

Query Match      0.8%; Score 20.4; DB 10; Length 47;
Best Local Similarity 65.2%; Pred. No. 1.3e+05;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1060 TAAAGCACCTTAAGGACCTTTACTGCCACAATCAGATTAAATTTGG 1105
DB 2 TTAACACATTGATGAATCTTTACTACTACAAAAGGTTGCGATTAG 47

RESULT 9
US-09-901-484A-206
; Sequence 206, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; FILE OF INVENTION: Prostate Cancer Gene
; FILE REFERENCE: GEN-T11XG3D2
; CURRENT APPLICATION NUMBER: US/09/901,484A
; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: US 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 09/218,207
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: US 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/853,526
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 206
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: (1)...(47)
; OTHER INFORMATION: polymorphic fragment 4-50-323
; NAME/KEY: allele
; LOCATION: (24)...(24)
; OTHER INFORMATION: polymorphic base C
; NAME/KEY: primer_bind
; LOCATION: (1)...(23)
; OTHER INFORMATION: potential microsequencing oligo 4-50-323.mis1
; NAME/KEY: primer_bind
; LOCATION: (25)...(47)
; OTHER INFORMATION: complement potential microsequencing oligo 4-50-323.mis2
US-09-901-484A-206

Query Match      0.8%; Score 20.4; DB 10; Length 47;
Best Local Similarity 65.2%; Pred. No. 1.3e+05;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1060 TAAAGCACCTTAAGGACCTTTACTGCCACAATCAGATTAAATTTGG 1105
```

[illegible]

Patent No. US20020150891A1
GENERAL INFORMATION:
APPLICANT: Hood, Leroy E.
APPLICANT: Roven, Lee F.
APPLICANT: Koop, Ben F.
TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH
NUMBER OF SEQUENCES: 1279
CORRESPONDENCE ADDRESS:
ADDRESSES: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/263,959
FILING DATE: 05-MAR-1999
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 486:
SEQUENCE CHARACTERISTICS:
LENGTH: 45 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-486
Query Match: 0.8%; Score 19.8; DB 10; Length 45;
Best Local Similarity 77.4%; Pred. No. 1.7e+05;
Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Oy 1176 TTTTATTTCTTAACATTTCTTTTCTAT 1206
Db 2 TTTCTTTCTTTCTTTCTTTTCTTTT 32
Search completed: March 9, 2003, 21:49:51
Job time : 199 secs

LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-729-402-28
Query Match: 0.8%; Score 19.8; DB 10; Length 41;
Best Local Similarity 69.2%; Pred. No. 1.5e+05;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Oy 707 TGCAGCAGCCACTCAGCGGTACTACCATTTCTACAGTA 745
Db 39 TGCAGCAGCCACTTAATCTGTATCATAATTTCTAGAATA 1
RESULT 14
US-09-921-398-18
Sequence 18, Application US/09921398
Patent No. US20020055169A1
GENERAL INFORMATION:
APPLICANT: Tekamp-Olson, Patricia
TITLE OF INVENTION: METHOD FOR EXPRESSION OF HETEROLOGOUS
PROTEINS IN YEAST
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell Seltzer IP Group of Alston & Bird, LLP
STREET: 3605 Glenwood Ave. Suite 310
CITY: Raleigh
STATE: NC
COUNTRY: US
ZIP: 27622
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/921,398
FILING DATE: 02-Aug-2001
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Sprull, W. Murray
REGISTRATION NUMBER: 32,943
REFERENCE/DOCKET NUMBER: 5784-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919 420 2202
TELEFAX: 919 881 3175
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 45 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-921-398-18
Query Match: 0.8%; Score 19.8; DB 10; Length 45;
Best Local Similarity 69.2%; Pred. No. 1.7e+05;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Oy 798 GTTCAAGTCGCTCTGGAGAGCTACAAATACAGATT 836
Db 2 GTTCAAGTTAACTCTGGTCAAGTTCAATCTTCTAGCTT 40
RESULT 15
US-09-263-959-486
Sequence 486, Application US/09263959

OK nucleic - nucleic search, using sw model

Run on: March 9, 2003, 18:54:42 ; Search time 3109 Seconds
(without alignments)
12783.443 Million cell updates/sec

Title: US-09-973-827-3
Perfect score: 2454
Sequence: 1 cggcgaggaggttagtttg.....totgtatttggatatcatc 2454

Scoring table: IDENTITY_NUC
Gapop 10.0, Capext 1.0.

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 102860

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0A
Maximum Match 100A
Listing first 45 summaries

Database :

EST:*

- 1: em_estba:*
- 2: em_esthum:*
- 3: em_estin:*
- 4: em_estnu:*
- 5: em_estov:*
- 6: em_estpl:*
- 7: em_estro:*
- 8: em_htc:*
- 9: gb_estli:*
- 10: gb_est2:*
- 11: gb_htc:*
- 12: gb_est3:*
- 13: gb_est4:*
- 14: gb_est5:*
- 15: em_estfun:*
- 16: em_estom:*
- 17: gb_gss:*
- 18: em_gss_hum:*
- 19: em_gss_inv:*
- 20: em_gss_pin:*
- 21: em_gss_vit:*
- 22: em_gss_fun:*
- 23: em_gss_mam:*
- 24: em_gss_mus:*
- 25: em_gss_other:*
- 26: em_gss_pro:*
- 27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	44	1.8	50	9 AU107544	AU107544 AU107544
2	22.8	0.9	50	17 AZ663650	AZ663650 LM0543C23
C 3	22.6	0.9	46	9 AU014208	AU014208 AU014208
C 4	22.4	0.9	48	17 AZ361863	AZ361863 LM0106B17
C 5	22.2	0.9	46	9 AU014238	AU014238 AU014238
C 6	22	0.9	50	9 AA545213	AA545213 vj93e11.r

BI425819	50	13	BI425819	50	13	BI425819
AL757115	44	17	AL757115	44	17	AL757115
AZ820350	46	17	AZ820350	46	17	AZ820350
BJ063775	48	13	BJ063775	48	13	BJ063775
AV851679	46	10	AV851679	46	10	AV851679
AZ638328	43	17	AZ638328	43	17	AZ638328
AU014228	45	9	AU014228	45	9	AU014228
AV947975	46	10	AV947975	46	10	AV947975
AW333744	50	10	AW333744	50	10	AW333744
AL760388	46	17	AL760388	46	17	AL760388
AU103894	46	9	AU103894	46	9	AU103894
BM61575	49	17	BM61575	49	17	BM61575
AZ435166	43	17	AZ435166	43	17	AZ435166
HSK002460	45	2	HSK002460	45	2	HSK002460
BJ015738	46	13	BJ015738	46	13	BJ015738
BJ075979	46	13	BJ075979	46	13	BJ075979
AJ495559	50	9	AJ495559	50	9	AJ495559
BJ066224	50	13	BJ066224	50	13	BJ066224
AU269673	45	9	AU269673	45	9	AU269673
AL761682	45	17	AL761682	45	17	AL761682
HS89550	48	17	HS89550	48	17	HS89550
BM791446	50	17	BM791446	50	17	BM791446
AA509550	43	9	AA509550	43	9	AA509550
AZ620145	43	17	AZ620145	43	17	AZ620145
H98532	44	14	H98532	44	14	H98532
AZ427755	45	17	AZ427755	45	17	AZ427755
AZ766403	46	17	AZ766403	46	17	AZ766403
AZ592310	48	17	AZ592310	48	17	AZ592310
TA980040	49	17	TA980040	49	17	TA980040
AU103398	50	9	AU103398	50	9	AU103398
AL761349	32	17	AL761349	32	17	AL761349
AQ073791	40	17	AQ073791	40	17	AQ073791
TA105A11P	40	17	TA105A11P	40	17	TA105A11P
AA946759	46	9	AA946759	46	9	AA946759
AW334262	46	10	AW334262	46	10	AW334262
B1256739	46	13	B1256739	46	13	B1256739
AL770028	46	17	AL770028	46	17	AL770028
AZ843462	47	17	AZ843462	47	17	AZ843462
HSK002436	48	2	HSK002436	48	2	HSK002436

ALIGNMENTS

RESULT 1	AU107544	50 bp	linear	EST 30-AUG-2001
LOCUS	AU107544	Sugano Homo sapiens cDNA library Homo sapiens cDNA clone		
DEFINITION	NBLAN589NF, mRNA sequence.			
ACCESSION	AU107544			
VERSION	AU107544.1	GI:13557065		
KEYWORDS	EST			
SOURCE	human.			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
AUTHORS	Suzuki Y., Tsunoda T., Tanaka T., Morishita S., Okubo K., Sakaki H., Ota T., Isogai T., Suyama A., Maruyama K., Sugano A. and Sugano S.			
TITLE	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites			
JOURNAL	EMBO Rep. 2 (5), 388-393 (2001)			
MEDLINE	21270072			
COMMENT	Contact: Yutaka Suzuki Department of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan Email: yusuk@med.s.u-tokyo.ac.jp Suzuki Y., Yoshimoto-Nakagawa K., Maruyama K., Sugano A. and Sugano S. a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997). Location/Qualifiers			
FEATURES				

source 1. .50
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="BLAN35NF"
 /note="Differential display comparison of untreated and dimethylfumarate treated U937 cells"
 BASE COUNT 8 a 6 c 25 g 11 t
 ORIGIN

Query Match 1.0%; Score 44; DB 9; Length 50;
 Best Local Similarity 100.0%; Pred. No. 42;
 Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCGCCGCGAGGTAGTTTACGCGGTGTGTACGTGGGGAGA 44
 |||||
 Db 7 CCGCCGCGAGGTAGTTTACGCGGTGTGTACGTGGGGAGA 50
 |||||

RESULT 2
 A2663650
 LOCUS
 DEFINITION IM0543G23F Mouse 10kb plasmid UUGCLM library Mus musculus genomic clone UUGCLM0543G23 F, DNA sequence.
 ACCESSION A2663650
 VERSION
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 50);
 Dunn, P., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Ross, R., Stokes, R., Tingey, A., von Niederhausen, A., and Wright, B., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb Plasmid Inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0543 row: G column: 23
 Seq primer: CGTGTAAACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 50.
 Location/Qualifiers
 1. .50
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone_lib="UUGCLM0543G23"
 /clone_lib="Mouse 10kb plasmid UUGCLM library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, P-"
 /note="Vector: PM042nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative

of pWD42 (914732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 15 a 17 c 5 g 13 t
 ORIGIN

Query Match 0.9%; Score 22.8; DB 17; Length 50;
 Best Local Similarity 71.4%; Pred. No. 1.6e+06;
 Matches 30; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 795 GTTGTTCAGCTCCCTGCGAGCGTACAAACATACGAGTT 836
 |||||
 Db 1 GTCTTTGACACTACTCTGCGACCTACACATACAGATT 42
 |||||

RESULT 3
 A0014208/c
 LOCUS
 DEFINITION A0014208 Schizosaccharomyces pombe late log phase cDNA Schizosaccharomyces pombe cDNA clone spc09381, mRNA sequence.
 ACCESSION A0014208
 VERSION
 KEYWORDS EST.
 SOURCE fission yeast.
 ORGANISM Schizosaccharomyces pombe
 Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes; Schizosaccharomycetales; Schizosaccharomycetaceae; Schizosaccharomyces.
 1 (bases 1 to 46)
 Morimyo, M. and Mita, K.
 Identification of expressed sequence tags of Schizosaccharomyces pombe
 Unpublished (1998)
 Contact: Mitsueki Morimyo
 Genome Research Group
 National Institute of Radiological Sciences
 9-1, Anagawa-4-chome, Inage-ku, Chiba 263-8555, Japan
 Email: morimyo@nirs.go.jp.
 Location/Qualifiers
 1. .46
 /organism="Schizosaccharomyces pombe"
 /strain="972"
 /db_xref="taxon:4896"
 /clone_lib="spc09381"
 /clone_lib="Schizosaccharomyces pombe late log phase cDNA"
 /sex="h minus"
 /note="Vector: M3mpl9; The cDNA library of Schizosaccharomyces pombe was prepared by cloning cDNA into the SmaI site of M3mpl9 DNA and the direction of DNA sequences was not always from 5' to 3'. The cDNA data of Schizosaccharomyces pombe are available for searching on the World Wide Web. (URL, http://www.nirs.go.jp)."
 the World Wide Web. (URL, http://www.nirs.go.jp)."
 BASE COUNT 22 a 5 c 3 g 15 t
 ORIGIN

Query Match 0.9%; Score 22.6; DB 9; Length 46;
 Best Local Similarity 67.4%; Pred. No. 1.8e+06;
 Matches 31; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 2122 TTATGAATGTACATGTGAGAAAATATCTGATTTTAAATATTTTC 2167
 |||||
 Db 46 TTTTTCACGTAAAGGTAGTATTATATGATTTTATAAAATTC 1
 |||||

RESULT 4
 A2361863
 LOCUS
 DEFINITION IM0106B17R Mouse 10kb plasmid UUGCLM library Mus musculus genomic clone UUGCLM0106B17 R, DNA sequence.

source 1. .50
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="BLAN35NF"
 /note="Differential display comparison of untreated and dimethylfumarate treated U937 cells"
 BASE COUNT 8 a 6 c 25 g 11 t
 ORIGIN

Query Match 1.0%; Score 44; DB 9; Length 50;
 Best Local Similarity 100.0%; Pred. No. 42;
 Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCGCCGCGAGGTAGTTTACGCGGTGTGTACGTGGGGAGA 44
 |||||
 Db 7 CCGCCGCGAGGTAGTTTACGCGGTGTGTACGTGGGGAGA 50
 |||||

RESULT 2
 A2663650
 LOCUS
 DEFINITION IM0543G23F Mouse 10kb plasmid UUGCLM library Mus musculus genomic clone UUGCLM0543G23 F, DNA sequence.
 ACCESSION A2663650
 VERSION
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 50);
 Dunn, P., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Ross, R., Stokes, R., Tingey, A., von Niederhausen, A., and Wright, B., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb Plasmid Inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0543 row: G column: 23
 Seq primer: CGTGTAAACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 50.
 Location/Qualifiers
 1. .50
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone_lib="UUGCLM0543G23"
 /clone_lib="Mouse 10kb plasmid UUGCLM library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, P-"
 /note="Vector: PM042nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative

ACCESSION AU014238
 VERSION AU014238.1 GI:3369029
 KEYWORDS EST.
 ORGANISM fission yeast.
 SOURCE Schizosaccharomyces pombe
 ORGANISM Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
 Schizosaccharomycetales; Schizosaccharomycetaceae;
 Schizosaccharomycetes.
 1 (bases 1 to 46)
 Morimyo,M. and Mita,K.
 Identification of expressed sequence tags of Schizosaccharomycetes
 Pomba
 Unpublished (1998)
 JOURNAL Contact: Mitsunori Morimyo
 COMMENT National Institute Of Radiological Sciences
 9-1, Anagawa-4 chome, Inage-ku, Chiba, Chiba 263-8555, Japan
 Email: morimyo@nirs.go.jp.
 Location/Qualifiers
 1. 46
 /organism="Schizosaccharomycetes pombe"
 /strain="972"
 /db_xref="taxon:4896"
 /clicne="spc09421"
 /clicne.lib="Schizosaccharomycetes pombe late log phase cdna"
 /sex="h minus"
 /note="vector: M13mp19; The cdna library of
 Schizosaccharomycetes pombe was prepared by cloning cdna
 into the SmaI site of M13mp19 DNA and the direction of
 sequences was not always from 5' to 3'. The cdna data of
 Schizosaccharomycetes pombe are available for searching on
 the World Wide Web. (URL, http://www.nirs.go.jp)"
 BASE COUNT 22 a 3 c 3 g 13 t 3 others
 ORIGIN
 Query Match 0.98; Score 22.2; DB 9; Length 46;
 Best Local Similarity 65.2; Pred. No. 2.2e+06;
 Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 2122 TTTTGAATGTTACATGATAGAAAATCTAGTTTAAATATATTC 2167
 Db 46 TTTTTCACGTGAAGAGTAGTATATATGATTTATTAATATTC 1
 RESULT 6
 AA545213/c
 LOCUS
 DEFINITION IMAGE:944684 3', mRNA sequence.
 ACCESSION AA545213
 VERSION AA545213.1 GI:2306287
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 50)
 Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
 Getzel,S., Kuback,T., Lacy,M., Le,M., Martin,J., Morris,M.,
 Schellenberg,K., Steptoe,K., Tan,F., Underwood,K., Moore,B.,
 Thelings,B., Wyllie,T., Lennon,G., Soares,B., Wilson,R. and
 Waterston,R.
 The WashU-HMI Mouse EST Project
 Unpublished (1996)
 JOURNAL Contact: Marra M/Mouse EST Project
 COMMENT WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LLNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.

```

/lab_host="DH10B"
/note=vector: pBluescript II SK+; Site_1: EcoRI; Site_2:
XhoI; The Clark NIL was constructed and seed was provided
by Dr. J. Specht, University of Nebraska (Shoemaker and
Specht, 1995). The cDNA library was constructed from mRNA
isolated from whole seedlings of 3 week old greenhouse
grown plants. Complementary DNA was synthesized from mRNA
using a primer consisting of a poly(dT) sequence with a
XhoI restriction site and a 3' anchor. EcoRI adapters were
ligated to the blunt-ended cDNA fragments followed by XhoI
digestion. The cDNA fragments were directionally cloned
into the EcoRI-XhoI restriction site of the pBluescript
vector. The ligated cDNA fragments were transformed into
DH10B host cells (GibcoBRL). The library was constructed
in cooperation with Dr. Paul Reim's laboratory at Northern
Arizona University."
BASE COUNT      10 a      7 c      26 t
ORIGIN

Query Match      0.98; Score 22; DB 13; Length 50;
Best Local Similarity 83.3%; Pred.No.2.4e+06;
Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY 1400 AGAATGAGGAAAGAAATCTTTTAAAA 1429
      ||||| ||||| ||||| ||||| || ||||
DB 40 AGAAGAAAGGAAAGAAATCTTATTATTA 11

RESULT 8
LOCUS AL757115.c
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-118A06-012518,
ACCESSION AL757115
VERSION AL757115.1 GI:21495463
KEYWORDS CSS,
SOURCE thale cress.
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
1 Strizhov, N., Li, Y., Rosso, M., Viehoever, P., Dekker, K., Saedler, H.
and Weissshaar, B.
A pipeline for automated high-throughput generation of FSTs
(flanking sequence tags) from Arabidopsis thaliana T-DNA
transformed lines
Unpublished
2 Rosso, M., Strizhov, N., Li, Y., Reiss, B., Dekker, K. and Weissshaar, B.
A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
for flanking sequence tag based reverse genetics
Unpublished
3 (bases 1 to 44)
Rosso, M., Strizhov, N., Li, Y. and Weissshaar, B.
Direct Submission
Submitted (17-JUN-2002) Weissshaar B., Max-Planck-Institut fuer
Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
This sequence is recovered from the left border of the T-DNA. It
indicates an insertion within the locus defined by clone l1111.
The sequences are generated at the MPI for Plant Breeding Research
in the context of the GABI-Kat project. GABI-Kat is part of the
German Plant Genomics program designated 'GABI'. Information on
line availability can be found at:
http://www.mpiz-koeln.mpg.de/GABI-Kat/.
Location/Qualifiers
1..44
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-118A06-012518"
/clone_l1b="Arabidopsis thaliana T-DNA insertion lines"
/note="PCR was performed on DNA from Arabidopsis thaliana"

FEATURES
Source

```

/l3b_host="E. Coli strain XL10-Gold, T1-resistant, F."
/notes=Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male); was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnates/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel

RESULT 11
AV851679/c

```

LOCUS      AV851679          46 bp      mRNA      linear      EST 08-NOV-2001
DEFINITION AV851679 Nori Satoh unpublished cDNA library, larva cDNA
VERSION     AV851679
KEYWORDS    EST.
SOURCE      AV851679.1 GI:16836144
ORGANISM    Ciona intestinalis.
            Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona;
            Phlebobranchia; Cionidae; Ciona.
REFERENCE   1 (bases 1 to 46)
AUTHORS     Satoh,N., Satou,Y., Kohara,Y. and Shin-I,T.
TITLE       Expressed genes in Ciona intestinalis
JOURNAL     Unpublished (2000)
COMMENT     Contact: Nori Satoh
            Department of Zoology
            Kyoto University
            Sakyo-Ku, Kyoto, Kyoto 606-8502, Japan
            Tel: 81-75-753-4081
            Fax: 81-75-705-1113
            Email: satoh@scid.ian.zool.kyoto-u.ac.jp.
FEATURES   Location/Qualifiers
            1..46
            /organism="Ciona intestinalis"
            /db_xref="taxon:7719"
            /clone_lib="Nori Satoh unpublished cDNA library, larva"
            /tissue_type="whole animal"
            /dev_stage="larva"
            /note="Vector: p Bluescript SK"
BASE COUNT 18 a 11 c 5 g 1 t 1 others
ORIGIN
Query Match      0.94; Score 21.4; DB 10; Length 46;
Best Local Similarity 70.0%; Pred. No. 3.2e+06;
Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 2087 CRAGATGCAATTAAGCAAGTATATATATATTTGTTAT 2126
      |||||  |||||  |||||  |||||  |||||  |||||
DB 45 CATGATGTCNTTTTACGAGGATACAGTTTGCTAT 6

RESULT 12
LOCUS      A2638328          43 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION 1M0498110F Mouse 10kb plasmid UUGCLM library Mus musculus genomic
            clone UUGCLM0498110 F, DNA sequence.
ACCESSION   A2638328
VERSION     A2638328.1 GI:11760518
KEYWORDS    GSS.
SOURCE      house mouse.
ORGANISM    Mus musculus.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus;
            1 (bases 1 to 43)
REFERENCE   1 (bases 1 to 43)
AUTHORS     Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,P., Haril,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            and Wright,D., Weiss,R., Stokes,R., Tingey,A., von Niederhausern,A.
            Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0498 row: 1 column: 10
            Seq Primer: CGTGTAAACGACGCCAGT

```

```

Class: plasmid ends
High quality sequence stop: 43.
Location/Qualifiers
1..43
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGCLM0498110"
/clone_lib="Mouse 10kb plasmid UUGCLM library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD22nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD22 (g11473211419b1A129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 6 a 1 c 1 g 35 t
ORIGIN
Query Match      0.94; Score 21.2; DB 17; Length 43;
Best Local Similarity 69.0%; Pred. No. 3.6e+06;
Matches 29; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1163 GACAAATATACATTTTATTTCTTAACATCTCTTTTCT 1204
      |||||  |||||  |||||  |||||  |||||  |||||
DB 1 GACAAATATTTTATTTTATTTTATTTTATTTTATTTT 42

RESULT 13
LOCUS      AU014228          45 bp      mRNA      linear      EST 03-AUG-1998
DEFINITION AU014228 Schizosaccharomyces pombe late log phase cDNA
            Schizosaccharomyces pombe cDNA clone spc09407, mRNA sequence.
ACCESSION   AU014228
VERSION     AU014228.1 GI:3369019
KEYWORDS    EST.
SOURCE      fission yeast.
ORGANISM    Schizosaccharomyces pombe
            Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
            Schizosaccharomycetales; Schizosaccharomycetaceae;
            Schizosaccharomycetes.
REFERENCE   1 (bases 1 to 45)
AUTHORS     Moriyama,M. and Mita,K.
TITLE       Identification of expressed sequence tags of Schizosaccharomyces
            pombe
JOURNAL     Unpublished (1998)
COMMENT     Contact: Mitsuoaki Moriyama
            Genome Research Group
            National Institute of Radiological Sciences
            9-1, Anagawa-4-chome, Inage-ku, Chiba 263-8555, Japan
            Email: moriyama@nirs.go.jp
            Location/Qualifiers
            1..45
            /organism="Schizosaccharomyces pombe"
            /strain="972"
            /db_xref="taxon:4896"
            /clone="spc09407"
            /clone_lib="Schizosaccharomyces pombe late log phase cDNA"
            /sex="h minus"

```

/note="Vector: M13mp19; The cDNA library of Schizosaccharomyces pombe was prepared by cloning cDNA into the SmaI site of M13mp19 DNA and the direction of DNA sequences was not always from 5' to 3'. The cDNA data of Schizosaccharomyces pombe are available for searching on the World Wide Web. (URL, <http://www.nirs.go.jp>)"

BASE COUNT 21 a 5 c 3 g 14 t 2 others

ORIGIN

Query Match 0.98; Score 21.2; DB 9; Length 45;

Best Local Similarity 67.48; Pred. No. 3.6e+06;

Matches 29; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

OY 2122 TTTATGAAATGTTACATGTAGAAAATACCTGATTTAAATATT 2164

||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 45 TTTTTCACGTGAAAGGTAGTATATATGATTTATATANAAT 3

RESULT 14

AV947975

LOCUS

AV947975 Nori Satoh unpublished cDNA library, young adult Ciona

intestinalis cDNA clone ciad05102 5', mRNA sequence.

ACCESSION AV947975

VERSION AV947975.1 GI:19425734

KEYWORDS EST.

SOURCE Ciona intestinalis.

ORGANISM Ciona intestinalis

Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona;

Phlebobranchia; Clonidae; Ciona.

REFERENCE 1 (bases 1 to 46)

AUTHORS Satoh,N., Satou,Y., Kohara,Y. and Shio-i,T.

TITLE Expressed genes in Ciona intestinalis

JOURNAL Unpublished (2000)

COMMENT Contact: Nori Satoh

Department of Zoology

Kyoto University

Sakyo-ku, Kyoto, Kyoto 606-8502, Japan

Tel: 81-75-753-4081

Fax: 81-75-705-1113

Email: satoh@ascidian.zool.kyoto-u.ac.jp.

Location/Qualifiers

1. .46

/organism="Ciona intestinalis"

/db_xref="taxon:7719"

/clone="ciad05102"

/clone_lib="Nori Satoh unpublished cDNA library, young adult"

/tissue_type="whole animal"

/dev_stage="young adult"

/note="Vector: pBluescript SK"

BASE COUNT 18 a 0 c 4 g 22 t 2 others

ORIGIN

Query Match 0.98; Score 21; DB 10; Length 46;

Best Local Similarity 69.28; Pred. No. 3.9e+06;

Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

OY 1176 TTTTATTTCTAAACATTTCTTTTCTATGCGCAAA 1214

||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2 TTTTATTTCTAAACATTTCTTTTCTATGCGCAAA 40

RESULT 15

AW333744

LOCUS

AW333744 S25E9 AGS-1 Pneumocystis carinii f. sp. carinii cDNA 3', mRNA

sequence.

ACCESSION AW333744

VERSION AW333744.1 GI:6830101

KEYWORDS EST.

SOURCE Pneumocystis carinii f. sp. carinii.

ORGANISM Pneumocystis carinii f. sp. carinii

Eukaryota; Fungi; Ascomycota; Pneumocystidomycetes;

Pneumocystidaceae; Pneumocystis.

REFERENCE 1 (bases 1 to 50)

AUTHORS Smilian,A.G., Arnold,J., Weise,M., Wunderlich,J., Staben,C., Edman

J.C., Kovacs,J. and Cushion,M.

TITLE Expressed sequence tags from Pneumocystis carinii

JOURNAL Unpublished (2000)

COMMENT Contact: Staben C

School of Biological Sciences

University of Kentucky

101 Morgan Building, University of Kentucky, Lexington, KY

40506-0225, USA

Tel: 606 257 2161

Fax: 606 257 1717

Email: staben@pop.uky.edu.

Location/Qualifiers

1. .50

/organism="Pneumocystis carinii f. sp. carinii"

/db_xref="taxon:38081"

/clone_lib="AGS-1"

/lab_host="E. coli"

/note="Vector: Lambda ZAP II; Site 1: EcoRI; Site 2: XhoI;

P. carinii organisms (3x10⁶) from a single rat (99-1-6,

sacrificed on 3/17/99) at Cincinnati VA facilities.

Trizol extracted RNA. Oligo dT priming, standard

conditions described by vendor, Stratagene. Further

details see www.uky.edu/project/Pneumocystis/

BASE COUNT 21 a 1 c 1 g 27 t

ORIGIN

Query Match 0.98; Score 21; DB 10; Length 50;

Best Local Similarity 66.78; Pred. No. 3.9e+06;

Matches 30; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

OY 2330 TTTTGTCTCTCTGTAAGAGAGTAGTATTAGTCTGCTTAA 2374

||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 4 TTTTGTCTCTCTGTAAGAGAGTAGTATTAGTCTGCTTAA 48

Search completed: March 9, 2003, 21:44:26

Job time : 3114 secs